Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
89 "Eun Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Article
Trajectory of Lymph Node Metastasis Reflects the Molecular Features of Esophageal Squamous Cell Carcinoma
Jiho Park, Seong Yong Park, Ha Eun Kim, Se-Young Jo, JeongSoo Won, Dae Joon Kim, Sangwoo Kim
Received March 5, 2025  Accepted October 14, 2025  Published online October 15, 2025  
DOI: https://doi.org/10.4143/crt.2025.257    [Accepted]
AbstractAbstract PDF
Purpose
Esophageal squamous cell carcinoma (ESCC) is frequently accompanied by lymph node metastasis (LNM) to the neck, chest, and abdomen. Despite its significance as a key prognostic factor, the genomic trajectory of LNM remains poorly understood. This study aimed to characterize the underlying patterns and genomic characteristics of LNM.
Materials and Methods
Whole-exome sequencing and transcriptome sequencing were performed on 45 multiregional samples (10 primary tumors, 10 normal esophageal tissues, and 25 lymph node tumors) from 10 ESCC patients who underwent esophagectomy with three-field lymphadenectomy. The temporal trajectory of metastasis was reconstructed through phylogenetic analysis, leveraging somatic mutations identified in the primary tumor and lymph nodes.
Results
Somatic mutations preceding metastasis included major driver mutations, such as TP53 and KMT2D, and displayed a mutational process associated with alcohol consumption (SBS16), emphasizing its influence on early tumorigenesis. In contrast, post-lymph node metastatic mutations were sporadic. Lymph nodes seeded later acquired mutations at a faster rate, suggesting increased genomic instability. In three of nine patients (33%), nodal skip metastasis (NSM) was observed, including two cases detected exclusively via genomic analysis, highlighting the necessity of phylogenetic assessment to avoid misclassification. Transcriptome analysis revealed activation of epithelial-mesenchymal transition and KRAS signaling pathways in NSM tumors, indicative of poor prognostic outcomes.
Conclusion
Our study provides a molecular understanding of LNM, emphasizes the potential importance of node-skipping patterns in ESCC, and underscores the utility of genomic analysis in elucidating the connection between LNM.
  • 419 View
  • 31 Download
Close layer
Special Articles
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2022
Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Kui Son Choi, Han-Kwang Yang, The Community of Population-Based Regional Cancer Registries
Cancer Res Treat. 2025;57(2):312-330.   Published online March 11, 2025
DOI: https://doi.org/10.4143/crt.2025.264
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2022, with international comparisons.
Materials and Methods
Cancer incidence, survival, and prevalence rates were calculated using the Korea National Cancer Incidence Database (1999-2022), with survival follow-up until December 31, 2023. Mortality data obtained from Statistics Korea, while international comparisons were based on GLOBOCAN data.
Results
In 2022, 282,047 newly diagnosed cancer cases (age-standardized rate [ASR], 287.0 per 100,000) and 83,378 deaths from cancer (ASR, 65.7 per 100,000) were reported. The proportion of localized-stage cancers increased from 45.6% in 2005 to 50.9% in 2022. Stomach, colorectal, and breast cancer showed increased localized-stage diagnoses by 18.1, 18.5, and 9.9 percentage points, respectively. Compared to 2001-2005, the 5-year relative survival (2018-2022) increased by 20.4 percentage points for stomach cancer, 7.6 for colorectal cancer, and 5.6 for breast cancer. Korea had the lowest cancer mortality among countries with similar incidence rates and the lowest mortality-to-incidence (M/I) ratios for these cancers. The 5-year relative survival (2018-2022) was 72.9%, contributing to over 2.59 million prevalent cases in 2022.
Conclusion
Since the launch of the National Cancer Screening Program in 2002, early detection has improved, increasing the diagnosis of localized-stage cancers and survival rates. Korea recorded the lowest M/I ratio among major comparison countries, demonstrating the effectiveness of its National Cancer Control Program.

Citations

Citations to this article as recorded by  
  • Explainable AI for colorectal cancer mortality and risk factor prediction in Korea: A nationwide cancer cohort study
    Sang Won Park, Na Young Yeo, Tae-Hoon Kim, Myoung Nam Lim, Inhyeok Yim, Oh Beom Kwon, Seung-Joo Nam, Hui-Young Lee, Woo Jin Kim
    International Journal of Medical Informatics.2026; 205: 106125.     CrossRef
  • Regional population decline and health screening uptake in Korean adults: nationwide study using multilevel regression analysis
    Wonjeong Jeong, Woorim Kim, Kyu-Tae Han
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • The Impact of Advanced Care Planning on Hospice Utilization in Patients with Cancer: A Nationwide Analysis in Korea
    Woorim Kim, Boram Kim, Minju Kim, Jin Young Choi
    Cancers.2025; 17(9): 1471.     CrossRef
  • Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment
    Geehyun Song, Whi-An Kwon, Eui Hyun Jung, Dai Hong Phuc Vo, Ho Trong Tan Truong, Ho Kyung Seo
    Journal of the Korean Medical Association.2025; 68(4): 215.     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shin Je Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyo
    International Journal of Thyroidology.2025; 18(1): 30.     CrossRef
  • The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy
    Tae Ho Hwang, Young Dong Yu, Kyung Hwa Choi, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park, Tae Heon Kim
    International Urology and Nephrology.2025;[Epub]     CrossRef
  • 2025 Korean Thyroid Association Clinical Management Guideline on Active Surveillance for Low-Risk Papillary Thyroid Carcinoma
    Eun Kyung Lee, Min Joo Kim, Seung Heon Kang, Bon Seok Koo, Kyungsik Kim, Mijin Kim, Bo Hyun Kim, Ji-hoon Kim, Shinje Moon, Kyorim Back, Young Shin Song, Jong-hyuk Ahn, Hwa Young Ahn, Ho-Ryun Won, Won Sang Yoo, Min Kyoung Lee, Jeongmin Lee, Ji Ye Lee, Kyon
    Endocrinology and Metabolism.2025; 40(3): 307.     CrossRef
  • A trial-ready cohort for finding unmet needs and improving quality of life among patients with esophageal cancer: a multicenter prospective cohort study
    Jiyoon Han, Genehee Lee, Juhee Cho, Somin You, Young Mog Shim, Yong Soo Choi, Jong Ho Cho, Seong Yong Park, Yeong Jeong Jeon, Junghee Lee, Danbee Kang, Hong Kwan Kim
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Current Status of the National Cancer Screening Program in Korea: History, Achievements, and Future Directions
    Kyeongmin Lee, Mina Suh, Kui Son Choi
    Journal of Preventive Medicine and Public Health.2025; 58(4): 337.     CrossRef
  • Incidence, mortality, and survival of gallbladder, extrahepatic bile duct, and pancreatic cancers in Korea: A population-based study from 1999 to 2022
    Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Kyu-Won Jung, Sang-Jae Park
    Annals of Hepato-Biliary-Pancreatic Surgery.2025; 29(3): 209.     CrossRef
  • Role of diabetes-related inflammation in pancreatic cancer evaluated by aptamer-based detection of circulating tumor cells in a streptozotocin-induced Panc02-transplanted murine model
    Yeshong Park, Sang-Tae Kim, Yu Mi Kim, Ho-Seong Han, Yoo-Seok Yoon
    Annals of Hepato-Biliary-Pancreatic Surgery.2025; 29(3): 343.     CrossRef
  • Deep learning mammography-based breast cancer risk model, its serial change, and breast cancer mortality
    Sujeong Shin, Yoosoo Chang, Seungho Ryu
    Breast Cancer.2025; 32(6): 1462.     CrossRef
  • COPS5 inhibition synergizes with the antitumor effect of trastuzumab by PTEN upregulation in HER2-amplified gastric cancer
    Sung-Hyun Hwang, Ji-Won Kim, Haeseong Park, Andrew J. Aguirre, Kui-Jin Kim, Songji Choi, Woochan Park, Jeongmin Seo, Heejung Chae, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Keun-Wook Lee
    Gastric Cancer.2025; 28(6): 1144.     CrossRef
  • Dietary Inflammatory Index and the Risk of Gastric Precancerous Lesions Among Korean Adults in a Rural Area
    Yewon Cho, Dongkyu Lee, Chang Soo Eun, Dong Soo Han, Hyun Ja Kim
    Nutrients.2025; 17(22): 3502.     CrossRef
  • The Influence of Work-Life Balance and Job Embeddedness on Turnover Intention among Nurses Caring for Cancer Patients
    Jin-young Park, Yeunhee Kwak, Jiwoo Jung, Seoung-Wha Lim
    Journal of Korean Critical Care Nursing.2025; 18(3): 28.     CrossRef
  • From Laparoscopy to Robotics: Navigating the Learning Curve in Colon Cancer Surgery Within a High-Volume East London District General Hospital
    Valentin Butnari, Jatinder Hayre, Olivia Pestrin, Ahmer Mansuri, Sandeep Kaul, Richard Boulton, Joseph Huang, Nirooshun Rajendran
    Surgical Innovation.2025;[Epub]     CrossRef
  • Serum Ferritin and Iron-Related Biomarkers in Relation to Breast Cancer Risk by Menopausal Status: A Prospective Cohort Study
    Eun Young Kim, Sujeong Shin, Yoosoo Chang, Seungho Ryu
    Cancer Epidemiology, Biomarkers & Prevention.2025; 34(11): 1946.     CrossRef
  • Prognostic factors in gastric cancer survivors comparing Cox proportional hazards and machine learning using a Korean National cohort
    Joonki Lee, Aesun Shin
    Discover Oncology.2025;[Epub]     CrossRef
  • Information Landscape on Cervical Cancer: An Analysis of News and Online Platform Data in the Republic of Korea
    Hye-Sun Lee, Gyeong-U Hong, Wonjeong Jeong, Kyounghee Oh, Jae Kwan Jun
    Health Communication.2025; : 1.     CrossRef
  • 12,868 View
  • 502 Download
  • 14 Web of Science
  • 19 Crossref
Close layer
Prediction of Cancer Incidence and Mortality in Korea, 2025
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Kui Son Choi, Han-Kwang Yang
Cancer Res Treat. 2025;57(2):331-338.   Published online March 11, 2025
DOI: https://doi.org/10.4143/crt.2025.263
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to project cancer incidence and mortality for 2025 to estimate Korea’s current cancer burden.
Materials and Methods
Cancer incidence data from 1999 to 2022 were obtained from the Korea National Cancer Incidence Database, while cancer mortality data from 1993 to 2023 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and then by multiplying the projected age-specific rates by the anticipated age-specific population for 2025. A joinpoint regression model was applied to identify significant changes in trends, using only the most recent trend data for predictions.
Results
A total of 304,754 new cancer cases and 84,019 cancer deaths are expected in Korea in 2025. The most commonly diagnosed cancer is projected to be thyroid cancer, followed by the colorectal, lung, breast, prostate and stomach cancers. These six cancers are expected to account for 63.8% of the total cancer burden. Lung cancer is expected to be the leading cause of cancer-related deaths, followed by liver, colorectal, pancreatic, stomach, and gallbladder cancers, together comprising 66.6% of total cancer deaths.
Conclusion
The increasing incidence of female breast cancer and the rise in prostate and pancreatic cancers are expected to continue. As aging accelerates, cancer commonly found in older adults are projected to rise significantly.

Citations

Citations to this article as recorded by  
  • The volume of Gleason grade group 1 prostate cancer at biopsy predicts unfavorable pathology but not upgrading after radical prostatectomy
    Tae Ho Hwang, Young Dong Yu, Kyung Hwa Choi, Seung Ryeol Lee, Young Kwon Hong, Dong Soo Park, Tae Heon Kim
    International Urology and Nephrology.2025;[Epub]     CrossRef
  • Factors That Impact the Quality of Life of Breast Cancer Patients: A Cross-Sectional Study
    Kyung-Sook Cha, Dohyun Lee, Su-Mi Im
    AJN, American Journal of Nursing.2025; 125(10): 20.     CrossRef
  • Association of plant-based diet indices with all-cause and cause-specific mortality among Korean adults in the KNHANES
    Heejin Lee, Jung Eun Lee, Minji Kang
    Scientific Reports.2025;[Epub]     CrossRef
  • 10,023 View
  • 356 Download
  • 2 Web of Science
  • 3 Crossref
Close layer
Original Articles
Detection Ability of Quality of Life Changes and Responsiveness of the KOQUSS-40 and the EORTC QLQ-C30/STO22 in Patients Who Underwent Gastrectomy: A Prospective Comparative Study
Bang Wool Eom, Keun Won Ryu, Ji Yeong An, Yun-Suhk Suh, In Cho, Sung Geun Kim, Ji-Ho Park, Hoon Hur, Hyung-Ho Kim, Sang-Hoon Ahn, Sun-Hwi Hwang, Hong Man Yoon, Ki Bum Park, Hyoung-Il Kim, In-Gyu Kwon, Han-Kwang Yang, Byoung-Jo Suh, Sang-Ho Jeong, Tae-Han Kim, Oh Kyoung Kwon, Hye-Seong Ahn, Ji Yeon Park, Ki Young Yoon, Myoung Won Son, Seong-Ho Kong, Young-Gil Son, Geum Jong Song, Jong Hyuk Yun, Jung-Min Bae, Do Joong Park, Sol Lee, Jun-Young Yang, Kyung Won Seo, You-Jin Jang, So Hyun Kang, Joongyub Lee, Hyuk-Joon Lee, on behalf of KOrean QUality of life in Stomach cancer patients Study group (KOQUSS)
Received November 20, 2024  Accepted February 28, 2025  Published online March 5, 2025  
DOI: https://doi.org/10.4143/crt.2024.1104    [Epub ahead of print]
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The aim of this study is to compare the detection ability of quality of life (QoL) changes and responsiveness of the KOrean QUality of life in Stomach cancer patients Study group (KOQUSS)-40 and European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ).
Materials and Methods
A multicenter prospective observational study was conducted to evaluate QoL changes after various gastrectomies between January 2021 and April 2022. Participants were instructed to complete the KOQUSS-40 and EORTC QLQ-C30/STO22 preoperatively and at 1, 3, 6, and 12 months postoperatively. QoL changes over time and QoL responsiveness were assessed for each questionnaire.
Results
Data from 491 patients who underwent curative gastrectomy for gastric cancer at 22 institutions were analyzed. The summary scores of the KOQUSS-40 and EORTC QLQ-STO22 showed significant differences between the total and proximal gastrectomy groups (p=0.044 and p=0.038, respectively), but no difference was observed for the EORTC QLQ-C30. Dysphagia on the KOQUSS-40 was significantly different between the total and proximal gastrectomy groups (p=0.031); however, dysphagia on the EORTC QLQ-STO22 did not differ. The responsiveness of the KOQUSS-40 was similar to that of the EORTC QLQ in patients who experienced ≥ 10% body weight loss, but approximately 10% less in patients receiving adjuvant chemotherapy than the EORTC QLQ.
Conclusion
KOQUSS-40 has several advantages over EORTC QLQ-C30/STO22 when comparing QoL between the total and proximal gastrectomy groups. The findings provide information for researchers investigating the QoL of patients who have undergone curative gastrectomy for gastric cancer.

Citations

Citations to this article as recorded by  
  • The efficacy of early progressive resistance exercise in the postoperative management of pancreaticoduodenectomy for pancreatic cancer: a randomized controlled trial
    Xuexue Liu, Neng Shi, Rui Li, Yuan Song
    Frontiers in Surgery.2025;[Epub]     CrossRef
  • 1,879 View
  • 94 Download
  • 1 Crossref
Close layer
General
Epidermal Growth Factor Receptor Aberrations Identified by Next-Generation Sequencing in Patients with Metastatic Cancers
Minkyue Shin, Dae-Ho Choi, Jaeyun Jung, Deok Geun Kim, Minae An, Sung Hee Lim, Seung Tae Kim, Jung Yong Hong, Se Hoon Park, Joon Oh Park, Kyoung-Mee Kim, Jeeyun Lee
Cancer Res Treat. 2025;57(4):932-941.   Published online February 21, 2025
DOI: https://doi.org/10.4143/crt.2024.564
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The epidermal growth factor receptor (EGFR) is a therapeutic target with confirmed clinical efficacy for several cancer types. We aimed to identify EGFR aberrations and their associations with other genomic alterations in patients with metastatic diseases of various cancers.
Materials and Methods
We used real-world data from the next-generation sequencing (NGS) of 3,286 patients with metastatic cancer at the Samsung Medical Center. We analyzed the distribution of EGFR amplification, mutation, and fusion, as well as their correlations with microsatellite instability (MSI), tumor mutation burden (TMB), and other gene aberrations.
Results
A total of 3,286 patients were tested using NGS of a panel covering 523 cancer-related genes (TSO500, Illumina) as part of clinical practice between October 2019 and October 2022. Patients with lung cancer and gliomas were not included in the analysis. Of the 3,286 patients, 175 (5.3%) had EGFR amplification, 38 (1.2%) had EGFR mutations, and eight (0.2%) had EGFR fusion. All 175 patients with EGFR amplifications had microsatellite-stable tumors, but 102 had co-amplifications in other cancer-related genes, and 78 had mutations with clinical significance (tier I/II). Among the 38 patients with EGFR mutations, three (8%) showed MSI-high status, and 11 (29%) demonstrated high TMB (≥ 10 mutations/Mb). Among eight patients with EGFR fusion, three exhibited possible functionalities of the EGFR gene.
Conclusion
EGFR aberrations, mainly amplification, followed by mutation and fusion, were present in 6.4% of patients with metastatic solid tumors.
  • 2,223 View
  • 105 Download
Close layer
Gastrointestinal cancer
Stereotactic Ablative Radiotherapy versus Surgery in Patients with Pulmonary Metastases from Colorectal Cancer
Byung min Lee, Ha Eun Kim, Young Ho Yang, Seung Yoon Yang, Han Sang Kim, Seo Hee Choi, Woong Sub Koom, Byung Jo Park, Jee Suk Chang
Cancer Res Treat. 2025;57(4):1135-1143.   Published online February 6, 2025
DOI: https://doi.org/10.4143/crt.2024.1040
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We compared the local control rate and toxicity of stereotactic ablative radiotherapy (SABR) versus wedge resection for colorectal pulmonary metastases.
Materials and Methods
We retrospectively reviewed medical charts and imaging of patients treated with SABR or wedge resection between 2010 and 2017 at a single institution.
Results
A total of 404 patients were treated with local therapy for 528 pulmonary metastatic lesions. While surgery was frequently used upfront for smaller, solitary metastases without other site involvement, SABR was often used for larger, multiple lesions and disease burdens beyond the lungs. The 3-year local control rate was 88.6% following surgery, which was not significantly different from that with SABR at 86.7% (p=0.174). No major postoperative complications or mortality were observed in the surgery group, and 2.8% of patients in the SABR group experienced grade 3-4 radiation pneumonitis.
Conclusion
SABR was used in patients with a higher risk of progression compared to those undergoing surgery, yet it has similar local control rates to wedge resection.

Citations

Citations to this article as recorded by  
  • Emerging Applications of Stereotactic Ablative Radiotherapy in Oligometastatic Colorectal Cancer
    Hasan Al-Sattar, Esele Okondo, Amir Mashia Jaafari, Inesh Sood, Jakob Hassan Dinif, Su Yin Lim, Charlotte Hafkamp, Irene Chong, Joao R. Galante, Sola Adeleke
    International Journal of Molecular Sciences.2025; 26(21): 10302.     CrossRef
  • 2,534 View
  • 168 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer
Seong-Eun Kim, Hyehyun Jeong, Sun Young Kim, Jeong Eun Kim, Yong Sang Hong, Deokhoon Kim, Jihun Kim, Ji Sung Lee, Tae Won Kim
Cancer Res Treat. 2025;57(4):1104-1114.   Published online January 10, 2025
DOI: https://doi.org/10.4143/crt.2024.569
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare clinicopathologic features and clinical outcomes of metastatic colorectal cancer (mCRC) based on epidermal growth factor receptor (EGFR) amplification status.
Materials and Methods
Patients with mCRC who underwent next-generation sequencing using a targeted 244-gene panel from 2016 to 2021 were identified and screened for EGFR copy numbers. Cases with at least five copies were reviewed for tumor purity adjustment, and those with an adjusted copy number of ≥ 6 were defined as EGFR-amplified (EGFR amp+). Their clinical characteristics were compared with those without EGFR amplification (EGFR amp–).
Results
Among 2,421 patients, 35 (1.4%) were EGFR amp+. Clinical characteristics did not significantly differ according to EGFR amplification status, but EGFR amp+ cases had fewer instances of peritoneal seeding (8.6% vs. 21.8%). Overall survival (OS) tended to be better in EGFR amp+ patients compared with EGFR amp– patients (median OS [mOS], 76 vs. 37 months; p=0.145). Among 572 patients who received anti-EGFR antibody–based chemotherapy (anti-EGFR CTx) during disease course, mOS tended to be better in 16 EGFR amp+ patients (79 months) compared with 556 EGFR amp– patients (39 months, p=0.048). Seven out of 35 EGFR amp+ patients were treated with front-line anti-EGFR CTx, and their progression-free survival did not differ from that of EGFR amp– patients treated with front-line anti-EGFR CTx (20 vs. 14 months, p=0.344).
Conclusion
This study may suggest a favorable predictive impact of EGFR amplification in patients treated with anti-EGFR CTx. However, the benefit of front-line anti-EGFR antibody treatment in this group was not notable.
  • 2,411 View
  • 90 Download
Close layer
Palliative medicine
Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
Yoon Jung Jang, Yun Jung Yang, Hoi Jung Koo, Hye Won Yoon, Seongbeom Uhm, Sun Young Kim, Jeong Eun Kim, Jin Won Huh, Tae Won Kim, Seyoung Seo
Cancer Res Treat. 2025;57(1):280-288.   Published online July 1, 2024
DOI: https://doi.org/10.4143/crt.2024.360
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In Korea, the Act on Hospice and Palliative Care and Decisions on Life-Sustaining Treatment (LST) was implemented on February 4, 2018. We aimed to investigate relevant factors and clinical changes associated with LST decisions after law enforcement.
Materials and Methods
This single-center retrospective study included patients who completed LST documents using legal forms at Asan Medical Center from February 5, 2018, to June 30, 2020.
Results
5,896 patients completed LST documents, of which 2,704 (45.8%) signed the documents in person, while family members of 3,192 (54%) wrote the documents on behalf of the patients. Comparing first year and following year of implementation of the act, the self-documentation rate increased (43.9% to 47.2%, p=0.014). Moreover, the number of LST decisions made during or after intensive care unit admission decreased (37.8% vs. 35.2%, p=0.045), and the completion rate of LST documents during chemotherapy increased (6.6% vs. 8.9%, p=0.001). In multivariate analysis, age < 65 (odds ratio [OR], 1.724; 95% confidence interval [CI], 1.538 to 1.933; p < 0.001), unmarried status (OR, 1.309; 95% CI, 1.097 to 1.561; p=0.003), palliative care consultation (OR, 1.538; 95% CI, 1.340 to 1.765; p < 0.001), malignancy (OR, 1.864; 95% CI, 1.628 to 2.133; p < 0.001), and changes in timing on the first year versus following year (OR, 1.124; 95% CI, 1.003 to 1.260; p=0.045) were related to a higher self-documentation rate.
Conclusion
Age < 65 years, unmarried status, malignancy, and referral to a palliative care team were associated with patients making LST decisions themselves. Furthermore, the subject and timing of LST decisions have changed with the LST act.
  • 3,444 View
  • 127 Download
Close layer
Review Article
Precision Oncology Clinical Trials: A Systematic Review of Phase II Clinical Trials with Biomarker-Driven, Adaptive Design
Hyerim Ha, Hee Yeon Lee, Jee Hyun Kim, Do Yeun Kim, Ho Jung An, SeungJin Bae, Hye-sung Park, Jin Hyoung Kang
Cancer Res Treat. 2024;56(4):991-1013.   Published online May 7, 2024
DOI: https://doi.org/10.4143/crt.2024.128
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety. We systematically reviewed and analyzed the target studies. EMBASE and PubMed searches from 2015 to 2023 generated 29 eligible trials. Data extraction included infrastructure, biomarker screening methodologies, efficacy, and safety profiles. Government agencies, cancer hospitals, and academic societies with accumulated experiences led investigator-initiated precision oncology clinical trials (IIPOCTs), which later guided sponsor-initiated precision oncology clinical trials (SIPOCTs). Most SIPOCTs were international studies with basket design. IIPOCTs primarily used the central laboratory for biomarker screening, but SIPOCTs used both central and local laboratories. Most of the studies adapted next-generation sequencing and/or immunohistochemistry for biomarker screening. Fifteen studies included an independent central review committee for outcome investigation. Efficacy assessments predominantly featured objective response rate as the primary endpoint, with varying results. Nine eligible studies contributed to the United States Food and Drug Administration’s marketing authorization. Safety monitoring was rigorous, but reporting formats lacked uniformity. Health-related quality of life and patient-reported outcomes were described in some protocols but rarely reported. Our results reveal that precision oncology trials with adaptive design rapidly and efficiently evaluate anticancer drugs’ efficacy and safety, particularly in specified biomarker-driven cohorts. The evolution from IIPOCT to SIPOCT has facilitated fast regulatory approval, providing valuable insights into the precision oncology landscape.

Citations

Citations to this article as recorded by  
  • Co-Encapsulation of Multiple Antineoplastic Agents in Liposomes by Exploring Microfluidics
    Sajid Asghar, Radu Iliescu, Rares-Ionut Stiufiuc, Brindusa Dragoi
    International Journal of Molecular Sciences.2025; 26(8): 3820.     CrossRef
  • Prospects of nanotechnology and natural products for cancer and immunotherapy
    Jan Filipe Andrade Santos, Marcela Bernardes Brasileiro, Pamela Danielle Cavalcante Barreto, Ligiane Aranha Rocha, José Adão Carvalho Nascimento Júnior
    Beilstein Journal of Nanotechnology.2025; 16: 1644.     CrossRef
  • Molecular Diagnostics and Personalized Therapeutics in Differentiated Thyroid Carcinoma: A Clinically Oriented Review
    Andrés Coca-Pelaz, Juan Pablo Rodrigo, Mark Zafereo, Iain Nixon, Pia Pace-Asciak, Gregory W. Randolph, Carlos Suárez, Alfio Ferlito
    Diagnostics.2025; 15(19): 2493.     CrossRef
  • A systematic review of intervertebral disc degeneration clinical trial protocols
    Francis Chemorion, Jerome Noailly, Marc-Antonio Bisotti
    Open Research Europe.2025; 5: 284.     CrossRef
  • Empiric or individually targeted antimicrobial therapy. Historical perspective and current state
    Andrea Mombelli, Lindsey Edwards, Luigi Nibali
    Periodontology 2000.2025;[Epub]     CrossRef
  • Evaluating Molecular and Immune Biomarkers in Predicting Bladder Cancer Recurrence and Survival: A Systematic Review
    Saad Masood, Abdullah Shaikh, Yasin Brar
    Cureus.2025;[Epub]     CrossRef
  • 5,829 View
  • 190 Download
  • 4 Web of Science
  • 6 Crossref
Close layer
Original Articles
Gastrointestinal cancer
Longitudinal Comparative Analysis of Circulating Tumor DNA and Matched Tumor Tissue DNA in Patients with Metastatic Colorectal Cancer Receiving Palliative First-Line Systemic Anti-Cancer Therapy
Seung-been Lee, Ji-Won Kim, Hong-Geun Kim, Sung-Hyun Hwang, Kui-Jin Kim, Ju Hyun Lee, Jeongmin Seo, Minsu Kang, Eun Hee Jung, Koung Jin Suh, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Jee Hyun Kim, Nak-Jung Kwon, Keun-Wook Lee
Cancer Res Treat. 2024;56(4):1171-1182.   Published online April 29, 2024
DOI: https://doi.org/10.4143/crt.2024.016
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare tumor tissue DNA (ttDNA) and circulating tumor DNA (ctDNA) to explore the clinical applicability of ctDNA and to better understand clonal evolution in patients with metastatic colorectal cancer undergoing palliative first-line systemic therapy.
Materials and Methods
We performed targeted sequencing analysis of 88 cancer-associated genes using germline DNA, ctDNA at baseline (baseline-ctDNA), and ctDNA at progressive disease (PD-ctDNA). The results were compared with ttDNA data.
Results
Among 208 consecutively enrolled patients, we selected 84 (41 males; median age, 59 years; range, 35 to 90 years) with all four sample types available. A total of 202 driver mutations were found in 34 genes. ttDNA exhibited the highest mutation frequency (n=232), followed by baseline-ctDNA (n=155) and PD-ctDNA (n=117). Sequencing ctDNA alongside ttDNA revealed additional mutations in 40 patients (47.6%). PD-ctDNA detected 13 novel mutations in 10 patients (11.9%) compared to ttDNA and baseline-ctDNA. Notably, seven mutations in five patients (6.0%) were missense or nonsense mutations in APC, TP53, SMAD4, and CDH1 genes. In baseline-ctDNA, higher maximal variant allele frequency (VAF) values (p=0.010) and higher VAF values of APC (p=0.012), TP53 (p=0.012), and KRAS (p=0.005) mutations were significantly associated with worse overall survival.
Conclusion
While ttDNA remains more sensitive than ctDNA, our ctDNA platform demonstrated validity and potential value when ttDNA was unavailable. Post-treatment analysis of PD-ctDNA unveiled new pathogenic mutations, signifying cancer’s clonal evolution. Additionally, baseline-ctDNA’s VAF values were prognostic after treatment.

Citations

Citations to this article as recorded by  
  • Precision-Guided Durable Response From Venetoclax With Decitabine in a Patient With a Metastatic Refractory IDH2 -Mutant Cholangiocarcinoma
    Eylül Özgü, Ünal Metin Tokat, Ashkan Adibi, Şevval Nur Bilgiç, Esranur Aydın, Onur Tutar, Mutlu Demiray
    JCO Precision Oncology.2025;[Epub]     CrossRef
  • Evolution of Neo-RAS-WT in Circulating Tumor DNA from First-Line to Subsequent Therapies in Metastatic Colorectal Cancer
    Marco Siringo, Michela De Meo, Irene Bottillo, Paola Grammatico, Enrico Cortesi, Chiara Nicolazzo, Paola Gazzaniga
    Cancers.2025; 17(7): 1070.     CrossRef
  • Liquid biopsy in gastrointestinal oncology: clinical applications and translational integration of ctDNA, CTCs, and sEVs
    Rita Palieri, Maria De Luca, Francesco Balestra, Giorgia Panzetta, Claudio Lotesoriere, Federica Rizzi, Angela Dalia Ricci, Rita Mastrogiacomo, Maria Lucia Curri, Luigi Andrea Laghi, Gianluigi Giannelli, Nicoletta Depalo, Maria Principia Scavo
    Oncology Reviews.2025;[Epub]     CrossRef
  • Circulating Tumor DNA as a Biomarker for Precision Medicine in Prostate Cancer: A Systematic Review
    Nouhaila Chanhih, Abdelilah Laraqui, Salma Hassine, Ahmed Ameur, Larbi Hamedoun, Hicham El Annaz, Rachid Abi, Mohamed Rida Tagajdid, Idriss Lahlou Amine, Khalid Ennibi, Abdelaziz Benjouad, Lamiae Belayachi
    International Journal of Molecular Sciences.2025; 26(22): 11049.     CrossRef
  • 5,058 View
  • 152 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
Association between Endoscopist Volume and Interval Cancers after Colonoscopy: Results from the National Colorectal Cancer Screening Program in Korea
Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Ji Eun Kim, Hooyeon Lee
Cancer Res Treat. 2024;56(4):1164-1170.   Published online April 16, 2024
DOI: https://doi.org/10.4143/crt.2024.009
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The rate of interval colorectal cancer (iCRC) is now accepted as a key performance indicator of organized colorectal cancer (CRC) screening programs. We aimed to examine the association between endoscopist volumes and the rate of iCRC among individuals with a positive fecal immunochemical test (FIT) within a nationwide population-based CRC screening program.
Materials and Methods
Individuals aged ≥ 50 years who underwent colonoscopy after a positive FIT from January 1, 2019 until December 31, 2020 in the Korean National Cancer Screening Program (KNCSP) were enrolled. We converted the data into per-endoscopist screening results, calculated the iCRC rates per endoscopist, and compared them to the previous year’s annual volume that was divided into five groups (V1, 1-9; V2, 10-29; V3, 30-59; V4, 60-119; V5, ≥ 120).
Results
A total of 10,412 endoscopists performed 216,907 colonoscopies. Overall, the average rate of iCRC per endoscopist was 8.46 per 1,000 examinations. Compared with the group with the highest volume (V5 group), the rate of iCRC was 2.21 times higher in the V1 group. Similar trends were observed in the other groups (V2: relative risks [RR], 2.15; 95% confidence interval [CI], 1.57 to 2.94; V3: RR, 1.56; 95% CI, 1.15 to 2.13; V4: RR, 1.18; 95% CI, 0.83 to 1.67).
Conclusion
The findings emphasize that endoscopists with lower procedure volumes have higher risks of interval cancer being missed or undetected. To maximize the preventative impact of colonoscopy for CRC, this issue should be addressed by monitoring endoscopist volumes and variations in performances.

Citations

Citations to this article as recorded by  
  • Biennial Mammography Performance in the Korean National Cancer Screening Program From 2009 to 2020
    Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Horim A. Hwang, Seung Eun Jung, Hooyeon Lee
    Korean Journal of Radiology.2025; 26(4): 313.     CrossRef
  • Preliminary reports of lung cancer screening with low-dose computed tomography: a nationwide performance on the Korean population in 2019–2020
    Horim A. Hwang, Dong Jun Kim, Nan-He Yoon, Jae Kwan Jun, Mina Suh, Sunhwa Lee, Seongju Kim, Seung Eun Jung, Hooyeon Lee
    European Radiology.2025; 35(9): 5492.     CrossRef
  • 3,576 View
  • 107 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
Special Articles
Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2021
Eun Hye Park, Kyu-Won Jung, Nam Ju Park, Mee Joo Kang, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo, The Community of Population-Based Regional Cancer Registries
Cancer Res Treat. 2024;56(2):357-371.   Published online March 13, 2024
DOI: https://doi.org/10.4143/crt.2024.253
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The current study provides national cancer statistics and their secular trends in Korea, including incidence, mortality, survival, and prevalence in 2021.
Materials and Methods
Incidence, survival, and prevalence rates of cancer were calculated using the Korea National Cancer Incidence Database, from 1999 to 2021, with survival follow-up until December 31, 2022. Deaths from cancer were assessed using causes-of-death data obtained from Statistics Korea.
Results
The number of new cancer diagnoses in 2021 increased by 27,002 cases (10.8%) compared to 2020. In 2021, newly diagnosed cancer cases and deaths from cancer were reported as 277,523 (age-standardized rate [ASR], 289.3 per 100,000) and 82,688 (ASR, 67.6 per 100,000), respectively. The overall cancer incidence rates increased by 3.3% annually from 1999 to 2012, and decreased by 5.3% from 2012 to 2015, thereafter, followed by non-significant changes. Cancer mortality rates have been decreasing since 2002, with more rapid decline in recent years (annual decrease of 2.8% from 2002 to 2013; 3.2% from 2013 to 2021). The 5-year relative survival between 2017 and 2021 was 72.1%, which contributed to prevalent cases reaching over 2.4 million in 2021.
Conclusion
In 2021, the number of newly diagnosed cancer patients increased as healthcare utilization recovered from the coronavirus disease 2019–related declines of 2020. Revised cancer registration guidelines expanded the registration scope, particularly for stomach and colorectal cancer. Survival rates have improved over the years, leading to a growing population of cancer survivors, necessitating a comprehensive cancer control strategy. The long-term impact of the pandemic on cancer statistics requires future investigation.

Citations

Citations to this article as recorded by  
  • Explainable AI for colorectal cancer mortality and risk factor prediction in Korea: A nationwide cancer cohort study
    Sang Won Park, Na Young Yeo, Tae-Hoon Kim, Myoung Nam Lim, Inhyeok Yim, Oh Beom Kwon, Seung-Joo Nam, Hui-Young Lee, Woo Jin Kim
    International Journal of Medical Informatics.2026; 205: 106125.     CrossRef
  • Increased risk of young-onset pancreatic cancer among adults aged 20–39 years with overweight or obesity, but not underweight: A nationwide cohort study
    Hyun-Jin Kim, Joo-Hyun Park, Jung Yong Hong, Kyungdo Han, Jay J. Shen, Joon Oh Park, Young Suk Park, Ho Yeong Lim
    European Journal of Cancer.2026; 232: 116111.     CrossRef
  • Association Between Plant-Based Diet Index and Breast Cancer Risk Stratified by Menopausal and Hormone Receptor Status: A Case-Control Study Among Korean Women
    Jeonghee Lee, Hyeongyeong Lee, Madhawa Gunathilake, So-Youn Jung, Jeongseon Kim
    Journal of Korean Medical Science.2026;[Epub]     CrossRef
  • Determining risk‐adapted starting age and interval for breast cancer screening based on reproductive and hormonal factors
    Tung Hoang, Jeonghee Lee, So‐Youn Jung, Jeongseon Kim
    International Journal of Cancer.2025; 156(9): 1692.     CrossRef
  • Survivorship concerns among posttreatment cancer survivors in South Korea: A secondary analysis of a cross-sectional survey
    Soo Hyun Kim
    International Journal of Nursing Studies.2025; 162: 104982.     CrossRef
  • Risk of malignant lymphoma in patients with previous tuberculosis infection: a cohort study
    Yun-Gyoo Lee, Dayeon Seo, Hyun-Il Gil, Dong-Hoe Koo, Suk Joong Oh
    Annals of Hematology.2025;[Epub]     CrossRef
  • Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline)
    In-Ho Kim, Seung Joo Kang, Wonyoung Choi, An Na Seo, Bang Wool Eom, Beodeul Kang, Bum Jun Kim, Byung-Hoon Min, Chung Hyun Tae, Chang In Choi, Choong-kun Lee, Ho Jung An, Hwa Kyung Byun, Hyeon-Su Im, Hyung-Don Kim, Jang Ho Cho, Kyoungjune Pak, Jae-Joon Kim
    Journal of Gastric Cancer.2025; 25(1): 5.     CrossRef
  • Sex Differences in Clinical Features and Survival Outcomes of Esophageal Cancer: A Comparative Study in the Korean Population
    Jin Hee Noh, Hyungchul Park, Do Hoon Kim, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Kee Don Choi, Ho June Song, Gin Hyug Lee, Hwoon-Yong Jung
    The World Journal of Men's Health.2025; 43(4): 969.     CrossRef
  • Factors Influencing Postoperative Quality of Life in Korean Brain Tumor Survivors
    Soomin Lim, Smi Choi-Kwon
    Journal of Neuroscience Nursing.2025; 57(2): 74.     CrossRef
  • A pharmacoinformatic approach for studying Atractylodes Lancea DC’s anticancer potential and control ROS-mediated apoptosis against prostate cancer cells
    Chi-Hoon Ahn, Ji Soo Myong, Kazi Rejvee Ahmed, Md Ataur Rahman, Md. Maharub Hossain Fahim, Min Choi, Muntajin Rahman, Jinwon Choi, Kiryang Kim, Seungjoon Moon, Mohammed Dalli, Rony Abdi Syahputra, Sang-Won Shin, Abdel Halim Harrath, Moon Nyeo Park, Bongle
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Evidence-based Korean guidelines for the clinical management of multiple myeloma: addressing 12 key clinical questions
    Sung-Hoon Jung, Youngil Koh, Min Kyoung Kim, Jin Seok Kim, Joon Ho Moon, Chang-Ki Min, Dok Hyun Yoon, Sung-Soo Yoon, Je-Jung Lee, Chae Moon Hong, Ka-Won Kang, Jihyun Kwon, Kyoung Ha Kim, Dae Sik Kim, Sung Yong Kim, Sung-Hyun Kim, Yu Ri Kim, Young Rok Do,
    Blood Research.2025;[Epub]     CrossRef
  • Dietary isoflavone intake among breast cancer survivors and cancer-free women
    Sihan Song, Hyeong-Gon Moon, Dong-Young Noh, So-Youn Jung, Eun Sook Lee, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Young Bum Yoo, Se Kyung Lee, Jeong Eon Lee, Seok Jin Nam, Yoo Seok Kim, Jun Won Min, Shinyoung Jun, Hyojee Joung, Jung Eun Lee
    Nutrition Research and Practice.2025; 19(1): 80.     CrossRef
  • Return-to-Work Support Needs and Influencing Factors Among Korean Young Adult Cancer Survivors: A Cross-Sectional Study
    Kisook Kim, Hyohyeon Yoon
    Oncology Nursing Forum.2025; 52(2): 151.     CrossRef
  • Principal component analysis and fine-tuned vision transformation integrating model explainability for breast cancer prediction
    Huong Hoang Luong, Phuc Phan Hong, Dat Vo Minh, Thinh Nguyen Le Quang, Anh Dinh The, Nguyen Thai-Nghe, Hai Thanh Nguyen
    Visual Computing for Industry, Biomedicine, and Art.2025;[Epub]     CrossRef
  • Author's responses to “Comment on Kim (2025) ‘Survivorship concerns among posttreatment cancer survivors in South Korea: A secondary analysis of a cross-sectional survey’”
    Soo Hyun Kim
    International Journal of Nursing Studies.2025; 166: 105039.     CrossRef
  • Post-gastrectomy anemia and ferritin dynamics: key determinants of prognosis and clinical management in patients with gastric cancer
    Eun Young Kim, Kyo Young Song, Dong Jin Kim
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • It is never too late to stop smoking. Applying working estimates of smoking cessation on five-year overall survival gains after a cancer diagnosis
    Nouhad El-Haddad, Yang Li, Geoff P. Delaney, Heewon Kang, Shalini Vinod, Margo Barr, Takahiro Tabuchi, Michael Kidd, Freddy Sitas
    Cancer Epidemiology.2025; 96: 102775.     CrossRef
  • A Urologist’s Perspective: Initial Experiences With SpaceOAR Hydrogel Insertion for Prostate Cancer Patients
    Hyunho Han, Ik Jae Lee, Woong Sub Koom, Chan Woo Wee, Woong Kyu Han
    Journal of Urologic Oncology.2025; 23(1): 20.     CrossRef
  • Laparoscopic and robotic surgery for colorectal cancer in Korea: a nationwide health insurance database analysis from 2019 to 2023
    Eun Ji Park, Hyun Gu Lee, Youn Young Park, Sun Jin Park, Kil Yeon Lee, Suk-Hwan Lee
    Journal of Minimally Invasive Surgery.2025; 28(1): 25.     CrossRef
  • Current status of endoscopy training for surgeons in Korea: a narrative review
    Dae Kyung Sohn
    Journal of Minimally Invasive Surgery.2025; 28(1): 1.     CrossRef
  • Cancer risk according to lifestyle risk score trajectories: a population-based cohort study
    Thi Minh Thu Khong, Thi Tra Bui, Hee-Yeon Kang, Eunjung Park, Moran Ki, Yoon-Jung Choi, Byungmi Kim, Jin-Kyoung Oh
    BJC Reports.2025;[Epub]     CrossRef
  • Mortality Risk According to Changes in Alcohol Consumption Post‐Diagnosis Among Liver Cancer Patients
    Thi Tra Bui, Eunjung Park, Hee‐Yeon Kang, Byungmi Kim, Young‐Joo Won, Jin‐Kyoung Oh
    Liver International.2025;[Epub]     CrossRef
  • Plasma metabolite based clustering of breast cancer survivors and identification of dietary and health related characteristics: an application of unsupervised machine learning
    Ga-Eun Yie, Woojin Kyeong, Sihan Song, Zisun Kim, Hyun Jo Youn, Jihyoung Cho, Jun Won Min, Yoo Seok Kim, Jung Eun Lee
    Nutrition Research and Practice.2025; 19(2): 273.     CrossRef
  • Time-trend costs of infection-related cancers in Japan: a systematic review
    Trinh Xuan Thi Nguyen, Sumeet Lal, Sulemana Abdul-Salam
    Discover Public Health.2025;[Epub]     CrossRef
  • Conditional Relative Survival of Gallbladder Cancer: A Population-Based Study in a High-Incidence Asian Country from 1999 to 2021
    Mee Joo Kang, Johyun Ha, Sang-Jae Park, Hyeong Min Park, Kyu-Won Jung, Sung-Sik Han
    Annals of Surgical Oncology.2025; 32(9): 6272.     CrossRef
  • Iron Consumption and Colorectal Cancer in Korean Adults: A Prospective Cohort Study
    Sukhong Min, Katherine De la Torre, Hyobin Lee, Woo-Kyoung Shin, Daehee Kang
    Nutrients.2025; 17(8): 1309.     CrossRef
  • Diagnosis and Treatment of HER2-Positive Breast Cancer
    Suee Lee
    The Korean Journal of Medicine.2025; 100(2): 81.     CrossRef
  • Evaluation of internal scatter contribution to gonadal dose in colorectal radiotherapy
    Hyojun Park, Jung-In Kim, Chang Heon Choi, Jong Min Park, Seonghee Kang, Hyeongmin Jin, Eui Kyu Chie, Jaeman Son
    Biomedical Physics & Engineering Express.2025; 11(3): 035009.     CrossRef
  • Hepatocellular carcinoma in Korea: an analysis of the 2016-2018 Korean Nationwide Cancer Registry
    Jihyun An, Young Chang, Gwang Hyeon Choi, Won Sohn, Jeong Eun Song, Hyunjae Shin, Jae Hyun Yoon, Jun Sik Yoon, Hye Young Jang, Eun Ju Cho, Ji Won Han, Suk Kyun Hong, Ju-Yeon Cho, Kyu-Won Jung, Eun Hye Park, Eunyang Kim, Bo Hyun Kim
    Journal of Liver Cancer.2025; 25(1): 109.     CrossRef
  • Use of Pulmonary Rehabilitation for Lung Cancer Patients in Korea: Analysis of the National Health Insurance Service Database
    Sang Hun Kim, Cho Hui Hong, Jong-Hwa Jeong, Jinmi Kim, Jeong Su Cho, Jin A Yoon, Jung Seop Eom, Byeong Ju Lee, Myung Hun Jang, Myung-Jun Shin, Yong Beom Shin
    Journal of Korean Medical Science.2025;[Epub]     CrossRef
  • Prediction of Cancer Incidence and Mortality in Korea, 2025
    Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Kui Son Choi, Han-Kwang Yang
    Cancer Research and Treatment.2025; 57(2): 331.     CrossRef
  • Changes in Cancer Care for Patients Aged 80 and Above: A Cohort Study from Samsung Comprehensive Cancer Center in South Korea
    Seung Tae Kim, Danbee Kang, Seok Jin Kim, Jun Ho Lee, Hong Kwan Kim, Yong Beom Cho, Yong Han Paik, Seok Won Kim, Byong Chang Jeong, Ho Jun Seol, Man Ki Chung, Kyu Taek Lee, Kihyun Kim, Sung-wook Seo, Jeong-Won Lee, Hee Chul Park, Dong Wook Shin, Juhee Cho
    Cancers.2025; 17(12): 2017.     CrossRef
  • Trends, patterns, and risk factors of esophageal cancer mortality in China, 2008–2021: A National Mortality Surveillance System data analysis
    Yunfei Jiao, Tinglu Wang, Lin Fu, Ye Gao, Zhiyuan Cheng, Lei Xin, Jinfang Xu, Han Lin, Wei Wang, Maigeng Zhou, Jinlei Qi, Zhaoshen Li, Luowei Wang
    Journal of Advanced Research.2025;[Epub]     CrossRef
  • Feasibility and preliminary efficacy of an artificial intelligence-based cancer survivorship care plan service using digital platforms: a single-arm prospective pilot study
    Soo Hyun Kim, Shin-Young Park, Sung Mook Lim, Hyemin Yi
    Journal of Cancer Survivorship.2025;[Epub]     CrossRef
  • Desorption and reusability of adsorbent Diaion HP-20 for the recovery of paclitaxel from culture supernatants of Taxus chinensis
    Yeji Kang, Jin-Hyun Kim
    Biotechnology and Bioprocess Engineering.2025; 30(3): 573.     CrossRef
  • The Development of Diagnostic Nuclear Medicine Imaging in Korea and Recent Trends in Radiopharmaceuticals for Pancreaticobiliary Diseases
    Byungwook Choi
    The Korean Journal of Pancreas and Biliary Tract.2025; 30(2): 62.     CrossRef
  • Personalizing perioperative therapy in muscle-invasive bladder cancer: balancing oncologic benefit, toxicity, and the risk of overtreatment
    Geehyun Song, Whi-An Kwon, Eui Hyun Jung, Dai Hong Phuc Vo, Ho Trong Tan Truong, Ho Kyung Seo
    Journal of the Korean Medical Association.2025; 68(4): 215.     CrossRef
  • Guidelines for the Treatment of Laryngeal Cancer from the Korean Society of Head and Neck Surgery
    Jeon Yeob Jang, Geun-Jeon Kim, Sang-Yeon Kim, Min-Su Kim, Dong Kun Lee, Minsu Kwon, Dongbin Ahn, Myung Jin Ban, Young Kang, Ho-Ryun Won, Jae Won Chang, Dong Won Lee, Ki Nam Park, Yeon Soo Kim, Ah Ra Jung, Jungirl Seok, Hye Ran Lee, Sung-Chan Shin, Chang M
    Clinical and Experimental Otorhinolaryngology.2025; 18(2): 89.     CrossRef
  • Changes in Physical Activity and Mortality Risk among Korean Cancer Survivors: A Population-Based Cohort Study
    Thi Tra Bui, Eunjung Park, Hee-Yeon Kang, Byungmi Kim, Jin-Kyoung Oh
    Cancer Epidemiology, Biomarkers & Prevention.2025; 34(6): 1016.     CrossRef
  • FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma
    Elizabeth C. Smyth, Kyoung-Mee Kim, Sun Young Rha, Zev A. Wainberg, Hayden Honeycutt, Erica Sommermann, Atsushi Ochiai
    Cancer Treatment Reviews.2025; 139: 102971.     CrossRef
  • Impact of Modifying Lazertinib Doses on Effectiveness and Safety in Patients With EGFR‐Positive Advanced Lung Cancer: A Multicenter, Prospective Observational Cohort Study
    Mi‐Hyun Kim, Min Ki Lee, Ji Eun Park, Sun Hyo Park, Tae Won Jang, Chi Young Jung, Insu Kim, Seong Hoon Yoon, June Hong Ahn, Hyun‐Kyung Lee, Jin Han Park, Sun Ha Choi, Jung Seop Eom
    Thoracic Cancer.2025;[Epub]     CrossRef
  • Cost-effectiveness of adding Helicobacter pylori screening to the National Gastric Cancer Screening Program in Korea (Preprint)
    Seowoo Bae, Joon Sung Kim, Moon Won Lee Lee, Gwang Ha Kim, Young-Il Kim, Woon Tae Jung, Gwang Ho Baik Baik, Beom Jin Kim, Joongyub Lee, Mina Suh, Jae Gyu Kim
    JMIR Research Protocols.2025;[Epub]     CrossRef
  • Insight into microbial extracellular vesicles as key communication materials and their clinical implications for lung cancer (Review)
    Jeong Yun Jang, Ji Hoon Seo, Jae Jun Choi, Hyun Jin Ryu, Hyunjun Yun, Dong Myeong Ha, Jinho Yang
    International Journal of Molecular Medicine.2025; 56(2): 1.     CrossRef
  • Prevalence of germline BRCA1/2 pathogenic variants in unselected Korean patients with HER2-negative metastatic breast cancer: a nationwide prospective study (KCSG BR19-10)
    Hee Kyung Ahn, Jee Hung Kim, Su-Jin Koh, Joohyuk Sohn, Myoung Joo Kang, Kyung Hae Jung, Kyoung Eun Lee, Jieun Lee, Sung Ae Koh, Yee Soo Chae, Jae Ho Byun, In Hae Park, Hee-Jun Kim, Jee Hyun Kim, Han Jo Kim, Joo Young Jung, Jung Lim Lee, Yoon Young Cho, Ky
    The Lancet Regional Health - Western Pacific.2025; 60: 101622.     CrossRef
  • Response to: Alcohol Cessation as a Multidisciplinary Imperative in Liver Cancer Survivorship: Clinical and Psychosocial Considerations
    Thi Tra Bui, Jin‐Kyoung Oh
    Liver International.2025;[Epub]     CrossRef
  • Confounding Effects of Lifestyle Factors in Cancer Risk Estimation for Occupational Radiation Exposure
    Eun Jung Park, Ye Jin Bang, Won Jin Lee
    Safety and Health at Work.2025; 16(3): 310.     CrossRef
  • Substantiation of Prostate Cancer Risk Calculator Based on Physical Activity, Lifestyle Habits, and Underlying Health Conditions: A Longitudinal Nationwide Cohort Study
    Jihwan Park
    Applied Sciences.2025; 15(14): 7845.     CrossRef
  • A Study on the Workload of Cytotechnologists: Focus on Commercial Laboratories
    Eun-Suk PARK
    Korean Journal of Clinical Laboratory Science.2025; 57(2): 228.     CrossRef
  • Effectiveness of the Human Papillomavirus Vaccine in Extended Age Groups: A Real-World Analysis Based on the Korean HPV Cohort Study
    Heekyoung Song, Sanha Lee, Suein Choi, Soo Young Hur
    Cancers.2025; 17(15): 2561.     CrossRef
  • Long‐Term Outcomes and Predictors in Cancer‐Related Stroke Using the Linked Data Set
    Tae Jung Kim, Ji Sung Lee, Mi Sun Oh, Soo‐Hyun Park, Kyung‐Ho Yu, Byung‐Chul Lee, Byung‐Woo Yoon, Sang‐Bae Ko
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Development, preliminary evaluation, and feasibility of a coping strategy and symptom management program for women with gynecological cancer undergoing chemotherapy
    Eungil Ko, Yaelim Lee
    Journal of Psychosocial Oncology.2025; : 1.     CrossRef
  • Enhancing TNM Stage Completeness Using the SEER Summary Stage: A Nationwide Study From Korea
    Chang Kyun Choi, Mina Suh, Kyu-Won Jung, E Hwa Yun
    Journal of Preventive Medicine and Public Health.2025; 58(4): 415.     CrossRef
  • Projected cancer burden attributable to population aging: Insight from a rapidly aging society
    Minh‐Thao Tu, Hoejun Kwon, Yoon‐Jung Choi, Hyunsoon Cho
    International Journal of Cancer.2025;[Epub]     CrossRef
  • Diagnosis and Management of Intraductal Papillary Mucinous Neoplasms: Focusing on Precancerous Lesions
    See Young Lee, Chan Min Jung, Jung Hyun Jo, Sung Ill Jang, Jae Hee Cho
    Journal of Digestive Cancer Research.2025; 13(2): 120.     CrossRef
  • Deep learning mammography-based breast cancer risk model, its serial change, and breast cancer mortality
    Sujeong Shin, Yoosoo Chang, Seungho Ryu
    Breast Cancer.2025; 32(6): 1462.     CrossRef
  • A higher intake of white-edible-colored fruits and vegetables is associated with lower gastrointestinal cancer risk among Korean adults in a prospective cohort study
    Yujin Cho, Jeonghee Lee, Madhawa Gunathilake, Youngyo Kim, Shinyoung Jun, Jeongseon Kim
    Nutrition Research.2025; 142: 1.     CrossRef
  • Mouth opening limitation induced by scarring in the supporting ligaments of the temporomandibular joint following maxillectomy: a 3D simulation study
    Mi-El Kim, Mi-Sun Kim, Ho-Beom Kwon
    Journal of Dental Rehabilitation and Applied Science.2025; 41(3): 169.     CrossRef
  • Exploring the Topoisomerase II Inhibitory Potential of Steroidal Drugs as a Recommended Mechanism of Action for Their Anticancer Activity: In Silico and In Vitro Assessments
    Ahmed A. Al‐Karmalawy, Mohamed E. Eissa, Ayman Abo Elmaaty, Tarek A. Yousef, Arwa Omar Al Khatib, Radwan Alnajjar, Faten Farouk, Amany Belal, Abdullah Yahya Abdullah Alzahrani, Marwa Sharaky
    Drug Development Research.2025;[Epub]     CrossRef
  • Prognostic Value of the Level of Urine Dipstick Proteinuria in Gastric Cancer in the Korean Population
    Yeo Ju Sohn, Sol Lee, Junghwa Kim, Insun Ryou, Eunjin Jeong, Jae-Hong Ryoo, Hyejin Chun
    Cancers.2025; 17(17): 2743.     CrossRef
  • Establishing consensus recommendations for metastatic hormone-sensitive prostate cancer in South Korea: A modified Delphi study
    Jae Young Joung, In Gab Jeong, Sung Gu Kang, Young Hwii Ko, Kyo Chul Koo, Kwang Hyun Kim, Myung Ki Kim, Soodong Kim, Jeong Hyun Kim, Sung-Woo Park, Jae Young Park, Wan Song, Seung Hwan Lee, Seung Il Jung, Jae Hoon Chung, Chang Wook Jeong, Kwan Joong Joo,
    Investigative and Clinical Urology.2025; 66(5): 416.     CrossRef
  • Pharmacologic Potential of Statins in Cancer Prevention: Colo-Rectal Cancer Risk in Dyslipidemic Patients from a Korean Nationwide Cohort
    Ho Suk Kang, Joo-Hee Kim, Heejin Kim, Joong Seob Lee, Hyo Geun Choi, Dae Myoung Yoo, Kyeong Min Han, Nan Young Kim, Kyueng-Whan Min, Mi Jung Kwon
    Pharmaceuticals.2025; 18(8): 1236.     CrossRef
  • Mistletoe in Cancer Cell Biology: Recent Advances
    Chang-Eui Hong, Su-Yun Lyu
    Current Issues in Molecular Biology.2025; 47(8): 672.     CrossRef
  • Early-onset Colorectal Cancer: Epidemiology, Risk Factors, and Prognosis
    Seung Bum Lee
    Journal of Digestive Cancer Research.2025; 13(2): 112.     CrossRef
  • Inequalities in breast cancer incidence and mortality in women with and without disabilities in South Korea: A population-based cohort study
    Hee-Yeon Kang, Eunjung Park, Thi Tra Bui, Byungmi Kim, Jin-Kyoung Oh
    Preventive Medicine Reports.2025; 59: 103242.     CrossRef
  • Comparative Analysis of Primary and Second Primary Multiple Myeloma: A Propensity Score-Matched Study
    Yoon Jung Jang, Joonseog Kong, Heyjin Kim, Chulkue Pak, Im Il Na, Hyo-Rak Lee, Hye Jin Kang
    Clinical Medicine Insights: Oncology.2025;[Epub]     CrossRef
  • Nutritional Counseling for Patients With Gastric Cancer After Subtotal Gastrectomy: A Randomized Clinical Trial
    Ah Ron Lee, Jae-Moon Bae, Min-Gew Choi, Ji Yeong An, Eun-Mee Kim, Boram Park
    Journal of Gastric Cancer.2025; 25(4): 593.     CrossRef
  • Impact of the 2024 medical-policy conflict on hepatocellular carcinoma management in Korea
    Soon Sun Kim, Hyun Yang, Jieun Kwon, Eunju Kim, Jeong Il Yu, Janghan Jung, Woosun Choi, Ji Eun Han, Moon Haeng Hur, Bo Hyun Kim, Sung Hyun Kim, Jeong Han Kim, Haeryoung Kim, Pyoung-Jae Park, Hyun Phil Shin, Su Jong Yu, Ki Tae Yoon, Sang Min Yoon, Minjong
    Journal of Liver Cancer.2025; 25(2): 169.     CrossRef
  • Long-term Survival Following Endoscopic Submucosal Dissection Versus Gastrectomy in Early Gastric Cancer Patients Aged 75 Years and Above: A National Retrospective Cohort Study in Korea
    Sangwon Lee, Yoon Jin Choi, Bang Wool Eom, Il Ju Choi, Choong-Kun Lee, Jungeun Park, Dong Ah Park, Kui Son Choi
    Journal of Gastric Cancer.2025; 25(4): 569.     CrossRef
  • Development of an Online-Based Self-Transcendence Promotion Program to Alleviate Psychological Distress in Survivors for Breast Cancer
    Yujung Jo
    Asian Oncology Nursing.2025; 25(3): 119.     CrossRef
  • Association of Elevated Serum Triglycerides with Colorectal Cancer Risk: Findings from a Large-scale Prospective Cohort of Korean Adults
    Sukhong Min, Hyobin Lee, Sinyoung Cho, Seung-Yong Jeong, Aesun Shin, Daehee Kang
    Cancer Prevention Research.2025; 18(11): 681.     CrossRef
  • National Colorectal Cancer Screening Program: Fecal Immunochemical Testing vs. Colonoscopy
    Han Hee Lee
    The Korean Journal of Gastroenterology.2025; 85(4): 435.     CrossRef
  • Acupuncture and Herbal Medicine Treatment in Cancer Care: A Scoping Review Focused on European Regions
    Kwonwoo Park, Jeong Su Park, Minji Kim, Gyumi Park, Yujin Lee, Hakyung Lee
    Perspectives on Integrative Medicine.2025; 4(3): 131.     CrossRef
  • Cancer risk in patients with systemic lupus erythematosus: a population-based cohort study in the Republic of Korea 2004–2021
    SJ Choi, S Lee, S Park, M Park, SW Choi, D-H Lim
    Scandinavian Journal of Rheumatology.2025; : 1.     CrossRef
  • Risk of colorectal cancer in kidney transplant recipients and patients with end-stage renal disease undergoing hemodialysis
    Yongchel Ahn, Hoon Yu, Yoonjong Bae, Mina Kim, Seung Bum Lee
    The Korean Journal of Internal Medicine.2025; 40(6): 952.     CrossRef
  • Corylin Exhibits Anticancer Activity by Inducing Apoptosis and G0/G1 Cell Cycle Arrest in SKOV3 Human Ovarian Cancer Cells
    Huiwon No, Jungeun Kim, Jin-Kyung Kim
    Biomolecules & Therapeutics.2025; 33(6): 975.     CrossRef
  • Long-Term Risk of Pneumonia Among Gastric Cancer Survivors: A Nationwide Population-Based Cohort Study
    Kyeong Min Han, Ho Suk Kang, Joo-Hee Kim, Hyo Geun Choi, Dae Myoung Yoo, Nan Young Kim, Ha Young Park, Mi Jung Kwon
    Cancers.2025; 17(22): 3688.     CrossRef
  • Association between body-mass index change and lung cancer risk in Korea: nested case-control study
    Ji-Woong Nam, Su-Eon Kim, Kyung-Min Lee, Ye-Won Jung, Jeong-Min Oh, Woo-Ri Lee, Young-Joo Won, Ki-Bong Yoo
    BMC Cancer.2025;[Epub]     CrossRef
  • Recent Trends in Hospice Utilization according to Service Type and Region in South Korea
    Woorim Kim, Kyuwoong Kim, Eun Jeong Nam, Su Yeon Kye, Minju Kim, Jin Young Choi
    Health Insurance Review & Assessment Service Research.2025; 5(2): 148.     CrossRef
  • Trends in the Characteristics of Patients with Lung Cancer in Incheon, Republic of Korea: A Population-Based Study from the Incheon Cancer Registry
    Jun Hyeok Lim, Hyun Young Lee, Hwan-Cheol Kim
    The Korean Journal of Medicine.2025; 100(6): 299.     CrossRef
  • Stage-Dependent Atrial Fibrillation Risk in Gastric Cancer: A Nationwide SEER-Based Cohort Study in South Korea
    Jin-Ho Park, So-Yeon Kim, Min-Su Choi
    Asian Journal of Current Research in Clinical Cancer.2025; 5(2): 97.     CrossRef
  • Colorectal Cancer Survivors' Inner Strength, Multiple Identities, and Quality of Life by Gender and Ostomy Presence: A Cross-Sectional Study
    Hannah Yu, Eunjung Ryu
    Korean Journal of Adult Nursing.2024; 36(2): 171.     CrossRef
  • Chuna Manual Therapy or Electroacupuncture with Pregabalin for Chemotherapy-Induced Peripheral Neuropathy: A Randomized Controlled Pilot Study
    Yeon-Woo Lee, Ilkyun Lee, Jin-Hyun Lee, Min-Geun Park, Ji-Hoon Kim, Yoon-Young Sunwoo, Man-Suk Hwang, Tae-Yong Park
    Journal of Clinical Medicine.2024; 13(13): 3916.     CrossRef
  • SMARCD3 Overexpression Promotes Epithelial–Mesenchymal Transition in Gastric Cancer
    Sun Yi Park, Ji-Ho Park, Jung Wook Yang, Eun-Jung Jung, Young-Tae Ju, Chi-Young Jeong, Ju-Yeon Kim, Taejin Park, Tae-Han Kim, Miyeong Park, Young-Joon Lee, Sang-Ho Jeong
    Cancers.2024; 16(12): 2282.     CrossRef
  • Factors influencing psychological distress among breast cancer survivors using machine learning techniques
    Jin-Hee Park, Misun Chun, Sun Hyoung Bae, Jeonghee Woo, Eunae Chon, Hee Jun Kim
    Scientific Reports.2024;[Epub]     CrossRef
  • The Influence of Professional Self-Concept and Patient Safety Culture on Burnout among Nurses in a Cancer Hospital
    Soyoon Do, Eunjung Ryu
    Asian Oncology Nursing.2024; 24(2): 53.     CrossRef
  • Prognostic Impact of Reactive Oxygen Species Modulator 1 in Surgically Resected Epidermal Growth Factor Receptor-Mutant Lung Adenocarcinomas
    Tae-Woo Kim, Kiyong Na, Junyang Jung, Heejin Lim, Hyewon Seo, Seung Hyeun Lee
    Oncology.2024; 102(11): 969.     CrossRef
  • Performance of the National Cancer Screening Program for Gastric Cancer in Korea
    Young-Il Kim
    The Korean Journal of Helicobacter and Upper Gastrointestinal Research.2024; 24(3): 231.     CrossRef
  • Sites of Metastasis and Survival in Metastatic Renal Cell Carcinoma: Results From the Korean Renal Cancer Study Group Database
    Chan Ho Lee, Minyong Kang, Cheol Kwak, Young Hwii Ko, Jung Kwon Kim, Jae Young Park, Seokhwan Bang, Seong Il Seo, Jungyo Suh, Wan Song, Cheryn Song, Hyung Ho Lee, Jinsoo Chung, Chang Wook Jeong, Jung Ki Jo, Seock Hwan Choi, Joongwon Choi, Changil Choi, Se
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Evolving trends in treatment patterns for hepatocellular carcinoma in Korea from 2008 to 2022: a nationwide population-based study
    Ji Won Han, Won Sohn, Gwang Hyeon Choi, Jeong Won Jang, Gi Hyeon Seo, Bo Hyun Kim, Jong Young Choi
    Journal of Liver Cancer.2024; 24(2): 274.     CrossRef
  • Redefining the role of radiation therapy in pancreatic cancer management: innovations and future directions: A narrative review
    Jeong Il Yu
    Precision and Future Medicine.2024; 8(3): 74.     CrossRef
  • A 5-Year Mortality Prediction Model for Prostate Cancer Patients Based on the Korean Nationwide Health Insurance Claims Database
    Joungyoun Kim, Yong-Hoon Kim, Yong-June Kim, Hee-Taik Kang
    Journal of Personalized Medicine.2024; 14(10): 1058.     CrossRef
  • Longitudinal trajectories of frailty and cognitive decline among older Korean cancer survivors
    Ran Won, Heesook Son, Jeehee Han, Youn-Jung Son
    Geriatric Nursing.2024; 60: 636.     CrossRef
  • Breast Cancer Statistics in Korea, 2021
    Chihwan David Cha, Chan Sub Park, Hee-Chul Shin, Jaihong Han, Jung Eun Choi, Joo Heung Kim, Kyu-Won Jung, Sae Byul Lee, Sang Eun Nam, Tae In Yoon, Young-Joon Kang, Zisun Kim, So-Youn Jung, Hyun-Ah Kim
    Journal of Breast Cancer.2024; 27(6): 351.     CrossRef
  • Tobacco Use in Korea: Current Epidemiology and Public Health Issues
    Jong Eun Park, Woo Min Jeong, Ye Jin Choi, So Young Kim, Kyoung Eun Yeob, Jong Hyock Park
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Endometrial cancer detected unusually after an ankle fracture secondary to severe anemia in an obese woman with heavy menstrual bleeding: A case report
    Hyung Yoon, Tae Go, Kyung Kim, Yong Song, Dong Suh, Ki Kim
    Molecular and Clinical Oncology.2024;[Epub]     CrossRef
  • Updates in the 2024 Korean Thyroid Association Clinical Practice Guidelines for Differentiated Thyroid Cancer: from Diagnosis to Initial Treatment
    Eun Kyung Lee
    International Journal of Thyroidology.2024; 17(2): 259.     CrossRef
  • A Case Study of Korean Medicine in Treating Worsened Esophagitis Symptoms Following Anticancer Therapy in a Patient with Esophageal Cancer
    Eun-seo Kim, Soo-min Jo, Si-young Song, Geun-jeong Kim, Young-su Lee
    The Journal of Internal Korean Medicine.2024; 45(5): 895.     CrossRef
  • The Emerging Treatment of BCG (Bacillus Calmette-Guérin)-Unresponsive Non–Muscle-Invasive Bladder Cancer
    Jong Ho Park, Jong Jin Oh
    Journal of Urologic Oncology.2024; 22(3): 246.     CrossRef
  • Adherence to the Cancer Prevention Recommendations from World Cancer Research Fund/American Institute for Cancer Research After Cancer Diagnosis on Mortality in South Korea
    Donghyun Won, Jeeyoo Lee, Sooyoung Cho, Ji Yoon Baek, Daehee Kang, Aesun Shin
    Nutrients.2024; 16(23): 4049.     CrossRef
  • Trends in Thyroid Cancer Mortality Rates in Korea: Insights from National Health Database
    Won Gu Kim
    Endocrinology and Metabolism.2024; 39(6): 853.     CrossRef
  • Impact of Early Oral Feeding on Postoperative Outcomes after Elective Colorectal Surgery: A Systematic Review and Meta-Analysis
    Soo Young Lee, Eon Chul Han
    Digestive Surgery.2024; : 1.     CrossRef
  • Nationwide Incidence Trends of Pediatric Parotid Malignancy in Korea and a Retrospective Analysis of Single-Institution Surgical Experience of Parotidectomy
    Hyun Seong Kim, Seo Young Kim, Eun-Jae Chung, Seong Keun Kwon, Soon-Hyun Ahn, Yuh-Seog Jung, Jungirl Seok
    Korean Society of Head and Neck Oncology.2024; 40(2): 7.     CrossRef
  • Total gastrectomy patients had a lower diet volume and greater diet frequency than distal gastrectomy patients after 6 months
    Ye-Ji Kim, Sang-Ho Jeong, Eun-Jung Jung, Taejin Park, Jin-Kwon Lee, Tae-Han Kim, Young-Hye Kim, Jae-Seok Min, Miyeong Park, Young-Joon Lee
    Medicine.2024; 103(51): e40878.     CrossRef
  • Quality of life outcomes in terminal cancer patients attending regional cancer centers in South Korea: protocol for a prospective cohort study
    Jung hye Kwon, Jung Hun Kang, Jung-Sik Huh, Su-Jin Koh, Kyu-Hyoung Lim, Byungho Choi, Rock Bum Kim, Young Jin Choi, Eun-Kee Song, Hyun Woo Lee, Ye-Seul Kim, Se-Il Go, Hwan Jung Yun, Sun Jin Sym, Hyewon Ryu, Myung-won Lee
    BMC Cancer.2024;[Epub]     CrossRef
  • Beyond survival: a comprehensive review of quality of life in rectal cancer patients
    Won Beom Jung
    Annals of Coloproctology.2024; 40(6): 527.     CrossRef
  • Post-colonoscopy Colorectal Cancer: Causes and Prevention
    Jong Yoon Lee
    Journal of Digestive Cancer Research.2024; 12(3): 160.     CrossRef
  • 16,746 View
  • 666 Download
  • 86 Web of Science
  • 106 Crossref
Close layer
Prediction of Cancer Incidence and Mortality in Korea, 2024
Kyu-Won Jung, Mee Joo Kang, Eun Hye Park, E Hwa Yun, Hye-Jin Kim, Jeong-Eun Kim, Hyun-Joo Kong, Jeong-Soo Im, Hong Gwan Seo
Cancer Res Treat. 2024;56(2):372-379.   Published online March 11, 2024
DOI: https://doi.org/10.4143/crt.2024.252
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to report the projected cancer incidence and mortality for the year 2024 to estimate Korea’s current cancer burden.
Materials and Methods
Cancer incidence data from 1999 to 2021 were obtained from the Korea National Cancer Incidence Database, and cancer mortality data from 1993 to 2022 were acquired from Statistics Korea. Cancer incidence and mortality were projected by fitting a linear regression model to observed age-specific cancer rates against their respective years and multiplying the projected age-specific rates by the anticipated age-specific population for 2024. A joinpoint regression model was used to determine the year in which the linear trend changed significantly; we only used the data of the latest trend for prediction.
Results
In total, 292,221 new cancer cases and 83,770 cancer deaths are expected to occur in Korea in 2024. The most common cancer site is expected to be the thyroid, followed by the colon and rectum, lung, breast, and stomach. These five cancers are expected to represent 55.7% of the overall burden of cancer in Korea. The most common type of cancer leading to death is expected to be lung cancer, followed by liver, colorectal, pancreatic, and stomach cancers.
Conclusion
The age-standardized incidence rates for female breast and prostate cancers are estimated to continue to increase. These up-to-date estimates of the cancer burden in Korea could be an important resource for planning and evaluating cancer-control programs.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of herbal medicine treatment on postsurgical recovery in gastric cancer patients: A systematic review and meta-analysis
    Soo-Dam Kim, Sook-Jin Pyo, Dong-Hyeon Kim, Hwa-Seung Yoo, So-Jung Park
    Medicine.2025; 104(1): e41034.     CrossRef
  • Comparison of definitive radiotherapy outcomes between younger and older patients with high- or very-high-risk prostate cancer
    Yong-Hyub Kim, Jae-Uk Jeong, Jung-Ho Yang, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Shinhaeng Cho, Sung-Ja Ahn
    Radiotherapy and Oncology.2025; 205: 110763.     CrossRef
  • Association Between Prostate Cancer Detection Rate and Year of Prostate Biopsy
    Young Jun Uhm, Woojin Bang, Jae Hoon Chung, Cheol Young Oh, Hwanik Kim, Jin Seon Cho
    Life.2025; 15(2): 260.     CrossRef
  • Association between sedentary behavior, depressive symptoms, and the risk of all-cause and cause-specific mortality among U.S. cancer survivors
    Ping Yao, Ying Zhong, Zhigong Wei
    BMC Cancer.2025;[Epub]     CrossRef
  • A Urologist’s Perspective: Initial Experiences With SpaceOAR Hydrogel Insertion for Prostate Cancer Patients
    Hyunho Han, Ik Jae Lee, Woong Sub Koom, Chan Woo Wee, Woong Kyu Han
    Journal of Urologic Oncology.2025; 23(1): 20.     CrossRef
  • Regional population decline and health screening uptake in Korean adults: nationwide study using multilevel regression analysis
    Wonjeong Jeong, Woorim Kim, Kyu-Tae Han
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Improved Prognostic Stratification With 2023 International Federation of Gynecology and Obstetrics Staging in Endometrial Cancer Reflecting Poor Prognosis of Aggressive Histological Types and p53 Abnormality
    Miseon Lee, Heesoo Yoon, Ujae Kim, Jun Kang, Yeon Bi Han, Keun Ho Lee, Sung Jong Lee, Sook Hee Hong, Dong Hoon Suh, Kidong Kim, Jae Hong No, Yong Beom Kim, Hyojin Kim, Ahwon Lee
    Laboratory Investigation.2025; 105(9): 104189.     CrossRef
  • Prognostic Significance of RBM3 Expression in Epithelial Ovarian Cancer: A Tissue Microarray-Based Study
    Hyeong Chan Shin, Hye Won Lee, So-Jin Shin, Sun Young Kwon
    Diagnostics.2025; 15(11): 1426.     CrossRef
  • Impact of fragmented care on cancer outcomes among korean women with breast and cervical cancer: a focus on regional and economic disparities
    Sun Jung Kim, Noorhee Son, Woo-Ri Lee, Dong-Woo Choi, Seojin Park, Kyu-Tae Han
    International Journal for Equity in Health.2025;[Epub]     CrossRef
  • Acid-resistant PVP/gold nanoparticles cluster for gastric juice-based metabolomics analysis
    Taeyeon Kim, Minsu Jang, Yeongjun Jeon, Seungwook Han, You Hwan Kim, Sunwoo Park, Hyeyun Lee, Woosok Moon, Tae-Young Jeong, Cheol Woong Choi, Jin-Woo Oh
    Sensors and Actuators Reports.2025; 10: 100370.     CrossRef
  • Recent Advances in Noninvasive Tests for Colorectal Cancer Screening
    Jae Seung Soh
    Journal of Digestive Cancer Research.2025; 13(2): 107.     CrossRef
  • Korean Medicine Treatment for Elderly Patients with Non-Small-Cell Lung Cancer: Case Reports
    Su-hyun Chin, Hayun Jin, Min-jun Lee, Dae-jun Choi, Beom-joon Lee, Hee-jae Jung, Kwan-il Kim
    The Journal of Internal Korean Medicine.2025; 46(3): 545.     CrossRef
  • Decisional Trade-offs in Localized Prostate Cancer: A Prospective Cross-Sectional Study of Radical Prostatectomy, Radiation Therapy, and Active Surveillance
    Hyunho Han, Youngdeuk Choi, Woong Kyu Han, Jihee Jung, Ayoung Yoo, Hyunji Yoon, Siyeong Lee, Changhwa Hyun, Woong Sub Koom, Ik Jae Lee, Chan Woo Wee, Jeongmi Lee, Jae Young Jeong, Hyung Ho Lee, Young Ae Kim, Jung Eun Kim, Songhee Eun, Sung Uk Lee, Jinha J
    Journal of Urologic Oncology.2025; 23(2): 112.     CrossRef
  • Comparative evaluation of two automated immunoassays for serum thyroglobulin quantification
    Kyoung Ho Roh, Hyunyong Hwang
    Kosin Medical Journal.2025; 40(3): 213.     CrossRef
  • Nutritional Counseling for Patients With Gastric Cancer After Subtotal Gastrectomy: A Randomized Clinical Trial
    Ah Ron Lee, Jae-Moon Bae, Min-Gew Choi, Ji Yeong An, Eun-Mee Kim, Boram Park
    Journal of Gastric Cancer.2025; 25(4): 593.     CrossRef
  • Risk Factors and Incidence of Reoperation in Direct-to-Implant Breast Reconstruction Surgery Among Patients with Breast Cancer
    Jin Ah Lee, Hye Sun Lee, Soyoung Jeon, Dooreh Kim, Young Joo Lee, Soo Youn Bae, Woo-Chan Park, Chang Ik Yoon, Jangyoun Choi
    Annals of Surgical Oncology.2025;[Epub]     CrossRef
  • The Burden of Pancreatic Cancer From Asia in 2022 and Predictions to 2050 According to GLOBOCAN Estimates
    Lin‐Kang Zhao, Jing Tu, Hong‐Xia Zuo, Fu‐Qiang Yin, Teng‐Yu Gao, Lu Meng, Long‐Chuan Xie, Chao Zhang
    Gut Medicine.2025;[Epub]     CrossRef
  • Trends in the Characteristics of Patients with Lung Cancer in Incheon, Republic of Korea: A Population-Based Study from the Incheon Cancer Registry
    Jun Hyeok Lim, Hyun Young Lee, Hwan-Cheol Kim
    The Korean Journal of Medicine.2025; 100(6): 299.     CrossRef
  • 2023 Update of the Korean Thyroid Association Guidelines for the Management of Thyroid Nodules
    Eun Kyung Lee, Young Joo Park
    Clinical Thyroidology®.2024; 36(4): 153.     CrossRef
  • The Role of Local Prostate and Metastasis-Directed Radiotherapy in the Treatment of Oligometastatic Prostate Cancer
    Seo Hee Choi, Seung-Hoon Beom, Young Deuk Choi, Won Sik Ham, Hyunho Han, Woong Kyu Han, Won Sik Jang, Seung Hwan Lee, Jaeho Cho
    Cancers.2024; 16(18): 3159.     CrossRef
  • Trend Analysis of Lung Cancer Incidence and Mortality in Xiamen (2011-2020)
    Jianni Cong, Jiahuang Chi, Junli Zeng, Yilan Lin
    Risk Management and Healthcare Policy.2024; Volume 17: 2375.     CrossRef
  • The Impact of the Dietary Inflammatory Index, Fasting Blood Glucose, and Smoking Status on the Incidence and Survival of Pancreatic Cancer: A Retrospective Case–Control Study and a Prospective Study
    Ga Hyun Lee, Yeon Hee Kim, Sang Myung Woo, Woo Jin Lee, Sung-Sik Han, Sang-Jae Park, Sherry Price, Penias Tembo, James R. Hébert, Mi Kyung Kim
    Nutrients.2024; 16(22): 3941.     CrossRef
  • 9,401 View
  • 349 Download
  • 15 Web of Science
  • 22 Crossref
Close layer
Original Articles
General
Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors
Yoon-Koo Kang, Min-Hee Ryu, Yong Sang Hong, Chang-Min Choi, Tae Won Kim, Baek-Yeol Ryoo, Jeong Eun Kim, John R. Weis, Rachel Kingsford, Cheol Hee Park, Seong Jang, Arlo McGinn, Theresa L. Werner, Sunil Sharma
Cancer Res Treat. 2024;56(3):743-750.   Published online January 18, 2024
DOI: https://doi.org/10.4143/crt.2023.980
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to report the results from an early-phase study of rivoceranib, an oral tyrosine kinase inhibitor highly selective for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
Materials and Methods
In this open-label, single-arm, dose-escalating, multicenter three-part phase 1/2a trial, patients had advanced solid tumors refractory to conventional therapy. Part 1 evaluated the safety and pharmacokinetics of five ascending once-daily doses of rivoceranib from 81 mg to 685 mg. Part 2 evaluated the safety and antitumor activity of once-daily rivoceranib 685 mg. Part 3 was conducted later, due to lack of maximum tolerated dose determination in part 1, to evaluate the safety and preliminary efficacy of once-daily rivoceranib 805 mg in patients with unresectable or advanced gastric cancer.
Results
A total of 61 patients were enrolled in parts 1 (n=25), 2 (n=30), and 3 (n=6). In parts 1 and 2, patients were white (45.5%) or Asian (54.5%), and 65.6% were male. The most common grade ≥ 3 adverse events were hypertension (32.7%), hyponatremia (10.9%), and hypophosphatemia (10.9%). The objective response rate (ORR) was 15.2%. In part 3, dose-limiting toxicities occurred in two out of six patients: grade 3 febrile neutropenia decreased appetite, and fatigue. The ORR was 33%.
Conclusion
The recommended phase 2 dose of rivoceranib was determined to be 685 mg once daily, which showed adequate efficacy with a manageable safety profile (NCT01497704 and NCT02711969).

Citations

Citations to this article as recorded by  
  • Advances in Targeted and Systemic Therapy for Salivary Gland Carcinomas: Current Options and Future Directions
    Sushanth Sreenivasan, Rahim Jiwani, Richard White, Veli Bakalov, Ryan Moll, Joseph Liput, Larisa Greenberg
    Current Oncology.2025; 32(4): 232.     CrossRef
  • Proteomics profiling reveals the potential targets of Apatinib inhibiting the proliferation of glioma U251 cell
    Yuyu Zhang, Yunshan Li, Fang Xu, Liangyu Pan, Saihang Zhang, Panpan Zhang, Xia Qin, Zuxiao Yang, Wei Yang, Wei Zhang, Dezhi Kong
    Biochemical and Biophysical Research Communications.2025; 775: 152148.     CrossRef
  • 5,587 View
  • 145 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Genitourinary cancer
Invasiveness of Upper Tract Urothelial Carcinoma: Clinical Significance and Integrative Diagnostic Strategy
Bokyung Ahn, Doeun Kim, Kye Jin Park, Ja-Min Park, Sun Young Yoon, Bumsik Hong, Yong Mee Cho, Deokhoon Kim
Cancer Res Treat. 2024;56(3):856-870.   Published online December 18, 2023
DOI: https://doi.org/10.4143/crt.2023.1150
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In this study, we aimed to determine the clinicopathologic, radiologic, and molecular significance of the tumor invasiveness to further stratify the patients with high-grade (HG) upper tract urothelial carcinoma (UTUC) who can be treated less aggressively.
Materials and Methods
Clinicopathologic and radiologic characteristics of 166 surgically resected HG UTUC (48 noninvasive, and 118 invasive) cases were evaluated. Six noninvasive UTUC cases with intratumoral tumor grade heterogeneity were selected for whole-exome sequencing (WES) to understand the underlying molecular pathophysiology. Barcode-tagging sequencing was done for validation of the target genes from WES data.
Results
Patients with noninvasive UTUC showed no cancer-specific death with better cancer-specific survival (p < 0.001) and recurrence-free survival (p < 0.001) compared to the patients with invasive UTUC. Compared to the invasive UTUC, noninvasive UTUC was correlated to a low grade (LG) on the preoperative abdominal computed tomography (CT) grading system (p < 0.001), histologic intratumoral tumor grade heterogeneity (p=0.018), discrepancy in preoperative urine cytology diagnosis (p=0.018), and absence of urothelial carcinoma in situ (p < 0.001). WES of the heterogeneous components showed mutually shared HRAS and FGFR3 mutations shared between the HG and LG components. HRAS mutation was associated with the lower grade on preoperative abdominal CT and intratumoral tumor grade heterogeneity (p=0.045 and p < 0.001, respectively), whereas FGFR3 mutation was correlated to the absence of carcinoma in situ (p < 0.001).
Conclusion
According to our comprehensive analysis, HG noninvasive UTUC can be preoperatively suspected based on distinct preoperative radiologic, cytologic, histologic, and molecular features. Noninvasive HG UTUC shows excellent prognosis and thus should be treated less aggressively.

Citations

Citations to this article as recorded by  
  • Papillary renal neoplasm with reverse polarity shows benign behavior: Results from a 77-case clinicopathological and molecular study
    Yong Il Lee, Ja-Min Park, Sun Young Yoon, Cheryn Song, Yong Mee Cho
    Annals of Diagnostic Pathology.2026; 80: 152498.     CrossRef
  • Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience
    Jianping Zhao, Yuan Shen, Ming Guo, Surena F Matin, Donna E Hansel, Charles C Guo
    American Journal of Clinical Pathology.2024;[Epub]     CrossRef
  • Clinical significance of tumor location for ureteroscopic tumor grading in upper tract urothelial carcinoma
    Satoshi Katayama, benjamin pradere, Nico C. Grossmann, Aaron M. Potretzke, Stephen J Boorjian, Alireza Ghoreifi, Siamak Daneshmand, Hooman Djaladat, John Sfakianos, Andrea Mari, Zine-Eddine Khene, David D'Andrea, Nozomi Hayakawa, Kazutoshi Fujita, Axel He
    Journal of Endourology.2024;[Epub]     CrossRef
  • Development and validation of a radiomics-based nomogram for predicting pathological grade of upper urinary tract urothelial carcinoma
    Yanghuang Zheng, Hongjin Shi, Shi Fu, Haifeng Wang, Xin Li, Zhi Li, Bing Hai, Jinsong Zhang
    BMC Cancer.2024;[Epub]     CrossRef
  • 4,537 View
  • 117 Download
  • 4 Web of Science
  • 4 Crossref
Close layer
General
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study
Songji Choi, Seyoung Seo, Ju Hyun Lee, Koung Jin Suh, Ji-Won Kim, Jin Won Kim, Se Hyun Kim, Yu Jung Kim, Keun-Wook Lee, Jwa Hoon Kim, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Sang-We Kim, Dae Ho Lee, Jae Cheol Lee, Chang-Min Choi, Shinkyo Yoon, Su-Jin Koh, Young Joo Min, Yongchel Ahn, Hwa Jung Kim, Jin Ho Baek, Sook Ryun Park, Jee Hyun Kim
Cancer Res Treat. 2024;56(2):404-413.   Published online November 7, 2023
DOI: https://doi.org/10.4143/crt.2023.784
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The female sex is reported to have a higher risk of adverse events (AEs) from cytotoxic chemotherapy. Few studies examined the sex differences in AEs and their impact on the use of medical services during adjuvant chemotherapy. This sub-study aimed to compare the incidence of any grade and grade ≥ 3 AEs, healthcare utilization, chemotherapy completion rate, and dose intensity according to sex.
Materials and Methods
This is a sub-study of a multicenter cohort conducted in Korea that evaluated the impact of healthcare reimbursement on AE evaluation in patients who received adjuvant chemotherapy between September 2013 and December 2016 at four hospitals in Korea.
Results
A total of 1,170 patients with colorectal, gastric, or non–small cell lung cancer were included in the study. Female patients were younger, had fewer comorbidities, and experienced less postoperative weight loss of > 10%. Females had significantly higher rates of any grade AEs including nausea, abdominal pain, stomatitis, vomiting, and neutropenia, and experienced more grade ≥ 3 neutropenia, nausea, and vomiting. The dose intensity of chemotherapy was significantly lower in females, and they also experienced more frequent dose reduction after the first cycle. Moreover, female patients receiving platinum-containing regimens had significantly higher rates of unscheduled outpatient visits.
Conclusion
Our study found that females experienced a higher incidence of multiple any-grade AEs and severe neutropenia, nausea, and vomiting, across various cancer types, leading to more frequent dose reductions. Physicians should be aware of sex differences in AEs for chemotherapy decisions.

Citations

Citations to this article as recorded by  
  • Toxicidad del esquema FOLFOX-6, asociado o no a bolo de 5-fluorouracilo, en cáncer colorrectal metastásico
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2025; 49(3): 154.     CrossRef
  • Cancer care for transgender and gender‐diverse people: Practical, literature‐driven recommendations from the Multinational Association of Supportive Care in Cancer
    Elizabeth J. Cathcart‐Rake, Alexandre Chan, Alvaro Menendez, Denise Markstrom, Carla Schnitzlein, Yee Won Chong, Don S. Dizon
    CA: A Cancer Journal for Clinicians.2025; 75(1): 68.     CrossRef
  • Characterisation of the effects of the chemotherapeutic agent paclitaxel on neuropathic pain-related behaviour, anxiodepressive behaviour, cognition, and the endocannabinoid system in male and female rats
    Chiara Di Marino, Álvaro Llorente-Berzal, Alba M. Diego, Ariadni Bella, Laura Boullon, Esther Berrocoso, Michelle Roche, David P. Finn
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • [Translated article] Toxicity of the FOLFOX-6 regimen, with or without 5-fluorouracil bolus, in metastatic colorectal cancer
    María Teresa Garrido Martínez, María Rodríguez Jorge, Ignacio García Giménez, María Isabel Guzmán Ramos, Salvador Grutzmancher Sáiz, Victoria Aviñó Tarazona
    Farmacia Hospitalaria.2025; 49(3): T154.     CrossRef
  • The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma
    Jun Kawashima, Yutaka Endo, Selamawit Woldesenbet, Mujtaba Khalil, Miho Akabane, François Cauchy, Feng Shen, Shishir Maithel, Irinel Popescu, Minoru Kitago, Matthew J. Weiss, Guillaume Martel, Carlo Pulitano, Luca Aldrighetti, George Poultsides, Andrea Ru
    Annals of Surgical Oncology.2025; 32(6): 4341.     CrossRef
  • Neurobehavioral manifestations in female rats after intermittent exposure to an anticancer agent, paclitaxel
    Deepika Pathak, K.P. Singh
    Behavioural Pharmacology.2025; 36(5): 276.     CrossRef
  • Gender‐Affirming Hormone Therapy: Pharmacokinetic Considerations for Oncology in Transgender Patients
    Anna Carollo, Lavinia Piazza, Alessio Provenzani
    Clinical and Translational Science.2025;[Epub]     CrossRef
  • 5,130 View
  • 178 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Breast cancer
Next-Generation Sequencing in Breast Cancer Patients: Real-World Data for Precision Medicine
Hyunwoo Lee, Yoon Ah Cho, Deok Geun Kim, Eun Yoon Cho
Cancer Res Treat. 2024;56(1):149-161.   Published online August 11, 2023
DOI: https://doi.org/10.4143/crt.2023.800
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Breast cancer is one of the most common causes of cancer-related death in females. Numerous drug-targetable biomarkers and predictive biomarkers have been developed. Some researchers have expressed doubts about the need for next-generation sequencing (NGS) studies in daily practice. This study analyzed the results of NGS studies on breast cancer at a single institute and evaluated the real-world applications of NGS data to precision medicine for breast cancer.
Materials and Methods
We retrospectively collected the results of NGS studies and analyzed the histopathologic features and genetic profiles of patients treated for breast cancer from 2010 to 2021. Seventy cases had data from CancerSCAN, a customized panel of 375 cancer-associated genes, and 110 cases had data from TruSight Oncology 500.
Results
The most frequently detected single nucleotide variant was the TP53 mutation (123/180, 68.3%), followed by PIK3CA mutations (51/180, 28.3%). Estrogen receptor 1 (ESR1) mutation was detected in 11 patients (6.1%), of whom 10 had hormone receptor–positive, human epidermal growth factor receptor 2–negative breast cancer, and two had no history of prior endocrine therapy. Based on their NGS study results, 13 patients (7.2%) received target therapy. Among them, four patients had a BRCA1 or BRCA2 germline mutation, and nine patients had a PIK3CA mutation.
Conclusion
NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.

Citations

Citations to this article as recorded by  
  • Harnessing Institutionally Developed Clinical Targeted Sequencing to Improve Patient Survival in Breast Cancer: A Seven-Year Experience
    Jiwon Koh, Jinyong Kim, Go-Un Woo, Hanbaek Yi, So Yean Kwon, Jeongmin Seo, Jeong Mo Bae, Jung Ho Kim, Jae Kyung Won, Han Suk Ryu, Yoon Kyung Jeon, Dae-Won Lee, Miso Kim, Tae-Yong Kim, Kyung-Hun Lee, Tae-You Kim, Jee-Soo Lee, Moon-Woo Seong, Sheehyun Kim,
    Cancer Research and Treatment.2025; 57(2): 443.     CrossRef
  • Comprehensive genomic profiling of Taiwanese triple-negative breast cancer with a large targeted sequencing panel
    Chi-Cheng Huang, Yi-Chen Yeh, Han-Fang Cheng, Bo-Fang Chen, Chun-Yu Liu, Yi-Fang Tsai, Hsiang-Ling Ho, Ling-Ming Tseng
    Journal of the Chinese Medical Association.2025; 88(8): 641.     CrossRef
  • Perceived Barriers to NGS-Based Molecular Profiling Among US Metastatic Breast Cancer Patients
    Nicholas Cadirov, Moumita Chaki, Olivia Foroughi, Omar Perez, Stella Redpath, Gary Gustavsen
    Diagnostics.2025; 15(20): 2626.     CrossRef
  • Detection of EGFR exon 20 insertion mutations in non-small cell lung cancer: implications for consistent nomenclature in precision medicine
    Jieun Park, Boram Lee, Ji-Young Song, Minjung Sung, Mi Jeong Kwon, Chae Rin Kim, Sangjin Lee, Young Kee Shin, Yoon-La Choi
    Pathology.2024; 56(5): 653.     CrossRef
  • Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer
    Elena Guerini-Rocco, Konstantinos Venetis, Giulia Cursano, Eltjona Mane, Chiara Frascarelli, Francesco Pepe, Mariachiara Negrelli, Edoardo Olmeda, Davide Vacirca, Alberto Ranghiero, Dario Trapani, Carmen Criscitiello, Giuseppe Curigliano, Christian Rolfo,
    Critical Reviews in Oncology/Hematology.2024; 201: 104427.     CrossRef
  • An ultra-sensitive and rapid immunosensor for the onsite detection of circulating tumor DNA in breast cancer
    Yi Bi, Xiao Lv, Ke Wang, Jinyu Wu, Xiang Shi, Xiaodong Zheng, Xiaogang Lin
    Frontiers in Bioengineering and Biotechnology.2024;[Epub]     CrossRef
  • NGS mutational status on first diagnostic tissue, liquid biopsy and mastectomy in G2–G3 breast cancer
    Carmen Maria Ardeleanu, Maria Victoria Olinca , Cristian Gabriel Viişoreanu , Horaţiu Alin Mureşan , Adriana Tecuceanu-Vulpe , Georgiana Manole , Iulia Elena Gune , Bianca Gălăţeanu , Andreea-Corina Ilie-Petrov
    Romanian Journal of Morphology and Embryology.2024; 65(2): 195.     CrossRef
  • 8,923 View
  • 409 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
General
Validation and Clinical Application of ONCOaccuPanel for Targeted Next-Generation Sequencing of Solid Tumors
Moonsik Kim, Changseon Lee, Juyeon Hong, Juhee Kim, Ji Yun Jeong, Nora Jee-Young Park, Ji-Eun Kim, Ji Young Park
Cancer Res Treat. 2023;55(2):429-441.   Published online November 25, 2022
DOI: https://doi.org/10.4143/crt.2022.891
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Targeted next-generation sequencing (NGS) is widely used for simultaneously detecting clinically informative genetic alterations in a single assay. Its application in clinical settings requires the validation of NGS gene panels. In this study, we aimed to validate a targeted hybridization capture-based DNA panel (ONCOaccuPanel) using the Illumina MiSeq sequencing platform. The panel allows the simultaneous detection of single-nucleotide variants (SNVs), insertions, deletions, and copy number changes of 323 genes and fusions of 17 genes in solid tumors.
Materials and Methods
We used 16 formalin-fixed paraffin-embedded (FFPE) tumor samples with previously known genetic mutations and one reference material (HD827) for validation. Moreover, we sequenced an additional 117 FFPE tumor samples to demonstrate the clinical utility of this panel.
Results
Validation revealed a 100% positive percentage agreement and positive predictive value for the detection of SNVs, insertions, deletions, copy number changes, fusion genes, and microsatellite instability–high types. We observed high levels of reproducibility and repeatability (R2 correlation coefficients=0.96-0.98). In the limit of detection assessment, we identified all clinically relevant genes with allele frequencies > 3%. Furthermore, the clinical application of ONCOaccuPanel using 117 FFPE samples demonstrated robust detection of oncogenic alterations. Oncogenic alterations and targetable genetic alterations were detected in 98.2% and 27.4% cases, respectively.
Conclusion
ONCOaccuPanel demonstrated high analytical sensitivity, reproducibility, and repeatability and is feasible for the detection of clinically relevant mutations in clinical settings.

Citations

Citations to this article as recorded by  
  • Risk prediction criteria for the primary hepatic perivascular epithelioid cell tumour family, including angiomyolipoma: analysis of 132 cases with a literature review
    Youngeun Yoo, Jihun Kim, In Hye Song
    Histopathology.2025; 86(6): 979.     CrossRef
  • Presence of RB1 or Absence of LRP1B Mutation Predicts Poor Overall Survival in Patients with Gastric Neuroendocrine Carcinoma and Mixed Adenoneuroendocrine Carcinoma
    In Hye Song, Bokyung Ahn, Young Soo Park, Deok Hoon Kim, Seung-Mo Hong
    Cancer Research and Treatment.2025; 57(2): 492.     CrossRef
  • Evaluation of potential of targeted sequencing through mutational signature simulation
    Keisuke Kodama, Yiwei Ling, Hiroshi Ichikawa, Toshifumi Wakai, Shujiro Okuda, Divijendra Natha Reddy Sirigiri
    PLOS One.2025; 20(6): e0326071.     CrossRef
  • Generation of orthotopic intracranial glioblastoma patient-derived xenograft models: insights into extrachromosomal DNA-driven MYC(N) and PDGFRA oncogene amplification and preliminary therapeutic evaluation
    Thi-Anh-Thuy Tran, Sinae An, Junghyun Lim, Young-Hee Kim, Ahyeon Shim, Taewoo Han, Hawsan Kim, Sue-Jee Park, Yeong Jin Kim, Kyung-Sub Moon, In-Young Kim, Shin Jung, Chul Won Lee, Kyung-Hwa Lee, Ae Kyung Park, Tae-Young Jung
    Neoplasia.2025; 69: 101233.     CrossRef
  • Primary Solid Pseudopapillary Tumor of the Ovary: A Case Report and Review of the Literature
    Juhun Lee, Seung Ho Song, In Hee Lee, Dong Ja Kim, Hyun Jung Lee
    Journal of Clinical Medicine.2024; 13(10): 2791.     CrossRef
  • Genome-scale mutational signature analysis in archived fixed tissues
    Bérénice Chavanel, François Virard, Vincent Cahais, Claire Renard, Cécilia Sirand, Kim M. Smits, Leo J. Schouten, Béatrice Fervers, Barbara Charbotel, Behnoush Abedi-Ardekani, Michael Korenjak, Jiri Zavadil
    Mutation Research - Reviews in Mutation Research.2024; 794: 108512.     CrossRef
  • Artificial intelligence algorithm for neoplastic cell percentage estimation and its application to copy number variation in urinary tract cancer
    Jinahn Jeong, Deokhoon Kim, Yeon-Mi Ryu, Ja-Min Park, Sun Young Yoon, Bokyung Ahn, Gi Hwan Kim, Se Un Jeong, Hyun-Jung Sung, Yong Il Lee, Sang-Yeob Kim, Yong Mee Cho
    Journal of Pathology and Translational Medicine.2024; 58(5): 229.     CrossRef
  • CDKN2A Homozygous Deletion Is a Stronger Predictor of Outcome than IDH1/2-Mutation in CNS WHO Grade 4 Gliomas
    Sang Hyuk Lee, Tae Gyu Kim, Kyeong Hwa Ryu, Seok Hyun Kim, Young Zoon Kim
    Biomedicines.2024; 12(10): 2256.     CrossRef
  • Comparison of immunohistochemistry and next-generation sequencing results in oncogenic PTEN missense mutations
    Moonsik Kim, Jinhee Kim, An Na Seo, Ji Yun Jeong, Nora Jee-Young Park, Gun Oh Chong, Dae Gy Hong, Ji Young Park
    Pathology - Research and Practice.2023; 251: 154879.     CrossRef
  • BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy
    Ji Hyun Oh, Chang Ohk Sung, Hyung-Don Kim, Sung-Min Chun, Jihun Kim
    Journal of Pathology and Translational Medicine.2023; 57(6): 323.     CrossRef
  • Clinical Application of the Association between Genetic Alteration and Intraoperative Fluorescence Activity of 5-Aminolevulinic Acid during the Resection of Brain Metastasis of Lung Adenocarcinoma
    Hyeon Yeong Jeong, Won Jun Suh, Seung Hwan Kim, Taek Min Nam, Ji Hwan Jang, Kyu Hong Kim, Seok Hyun Kim, Young Zoon Kim
    Cancers.2023; 16(1): 88.     CrossRef
  • 7,901 View
  • 217 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
Sarcoma
Whole-Genome and Transcriptome Sequencing Identified NOTCH2 and HES1 as Potential Markers of Response to Imatinib in Desmoid Tumor (Aggressive Fibromatosis): A Phase II Trial Study
Joonha Kwon, Jun Hyeong Lee, Young Han Lee, Jeeyun Lee, Jin-Hee Ahn, Se Hyun Kim, Seung Hyun Kim, Tae Il Kim, Kum-Hee Yun, Young Suk Park, Jeong Eun Kim, Kyu Sang Lee, Jung Kyoon Choi, Hyo Song Kim
Cancer Res Treat. 2022;54(4):1240-1255.   Published online January 17, 2022
DOI: https://doi.org/10.4143/crt.2021.1194
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Desmoid tumor, also known as aggressive fibromatosis, is well-characterized by abnormal Wnt/β-catenin signaling. Various therapeutic options, including imatinib, are available to treat desmoid tumor. However, the molecular mechanism of why imatinib works remains unclear. Here, we describe potential roles of NOTCH2 and HES1 in clinical response to imatinib at genome and transcriptome levels.
Materials and Methods
We identified somatic mutations in coding and noncoding regions via whole-genome sequencing. To validate the genetic interaction with expression level in desmoid-tumor condition, we utilized large-scale whole-genome sequencing and transcriptome datasets from the Pan-Cancer Analysis of Whole Genomes project. RNA-sequencing was performed using prospective and retrospective cohort samples to evaluate the expressional relevance with clinical response.
Results
Among 20 patients, four (20%) had a partial response and 14 (66.7%) had stable disease, 11 of which continued for ≥ 1 year. With gene-wise functional analyses, we detected a significant correlation between recurrent NOTCH2 noncoding mutations and clinical response to imatinib. Based on Pan-Cancer Analysis of Whole Genomes data analyses, NOTCH2 mutations affect expression levels particularly in the presence of CTNNB1 missense mutations. By analyzing RNA-sequencing with additional desmoid tumor samples, we found that NOTCH2 expression was significantly correlated with HES1 expression. Interestingly, NOTCH2 had no statistical power to discriminate between responders and non-responders. Instead, HES1 was differentially expressed with statistical significance between responders and non-responders.
Conclusion
Imatinib was effective and well tolerated for advanced desmoid tumor treatment. Our results show that HES1, regulated by NOTCH2, as an indicator of sensitivity to imatinib, and an important therapeutic consideration for desmoid tumor.

Citations

Citations to this article as recorded by  
  • Therapeutical potential of natural products in treatment of pancreatic cancer: a review
    Sanjeev Kumar Sahu, Pranav Kumar Prabhakar, Manish Vyas
    Molecular Biology Reports.2025;[Epub]     CrossRef
  • Advancing Precision Medicine: The Role of Genetic Testing and Sequencing Technologies in Identifying Biological Markers for Rare Cancers
    Joviana Farhat, Lara Alzyoud, Mohammad AlWahsh, Animesh Acharjee, Basem Al‐Omari
    Cancer Medicine.2025;[Epub]     CrossRef
  • The Notch signaling pathway in desmoid tumor: Recent advances and the therapeutic prospects
    Chuanxi Zheng, Jianghong Huang, Gang Xu, Wei Li, Xin Weng, Shiquan Zhang
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2024; 1870(1): 166907.     CrossRef
  • Long‐term result of 125I seed brachytherapy for pediatric desmoid tumor in the head and neck
    Yi‐Wei Zhong, Xiao‐Ming Lyu, Yan Shi, Chuan‐Bin Guo, Jian‐Guo Zhang, Lei Zheng
    Pediatric Blood & Cancer.2023;[Epub]     CrossRef
  • Update on Familial Adenomatous Polyposis-Associated Desmoid Tumors
    Wanjun Yang, Pei-Rong Ding
    Clinics in Colon and Rectal Surgery.2023; 36(06): 400.     CrossRef
  • Multimodality Imaging Assessment of Desmoid Tumors: The Great Mime in the Era of Multidisciplinary Teams
    Igino Simonetti, Federico Bruno, Roberta Fusco, Carmen Cutolo, Sergio Venanzio Setola, Renato Patrone, Carlo Masciocchi, Pierpaolo Palumbo, Francesco Arrigoni, Carmine Picone, Andrea Belli, Roberta Grassi, Francesca Grassi, Antonio Barile, Francesco Izzo,
    Journal of Personalized Medicine.2022; 12(7): 1153.     CrossRef
  • 8,890 View
  • 282 Download
  • 6 Web of Science
  • 6 Crossref
Close layer
Gastrointestinal cancer
Histopathologic and Molecular Biomarkers of PD-1/PD-L1 Inhibitor Treatment Response among Patients with Microsatellite Instability‒High Colon Cancer
Jaewon Hyung, Eun Jeong Cho, Jihun Kim, Jwa Hoon Kim, Jeong Eun Kim, Yong Sang Hong, Tae Won Kim, Chang Ohk Sung, Sun Young Kim
Cancer Res Treat. 2022;54(4):1175-1190.   Published online January 12, 2022
DOI: https://doi.org/10.4143/crt.2021.1133
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Recent clinical trials have reported response rates < 50% among patients treated with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors for microsatellite instability‒high (MSI-H) colorectal cancer (CRC), and factors predicting treatment response have not been fully identified. This study aimed to identify potential biomarkers of PD-1/PD-L1 inhibitor treatment response among patients with MSI-H CRC.
Materials and Methods
MSI-H CRC patients enrolled in three clinical trials of PD-1/PD-L1 blockade at Asan Medical Center (Seoul, Republic of Korea) were screened and classified into two groups according to treatment response. Their histopathologic features and expression of 730 immune-related genes from the NanoString platform were evaluated, and a machine learning–based classification model was built to predict treatment response among MSI-H CRCs patients.
Results
A total of 27 patients (15 responders, 12 non-responders) were included. A high degree of lymphocytic/neutrophilic infiltration and an expansile tumor border were associated with treatment response and prolonged progression-free survival (PFS), while mucinous/signet-ring cell carcinoma was associated with a lack of treatment response and short PFS. Gene expression profiles revealed that the interferon-γ response pathway was enriched in the responder group. Of the top eight differentially expressed immune-related genes, PRAME had the highest fold change in the responder group. Higher expression of PRAME was independently associated with better PFS along with histologic subtypes in the multivariate analysis. The classification model using these genes showed good performance for predicting treatment response.
Conclusion
We identified histologic and immune-related gene expression characteristics associated with treatment response in MSI-H CRC, which may contribute to optimal patient stratification.

Citations

Citations to this article as recorded by  
  • The Relationship of PRAME Expression with Clinicopathologic Parameters and Immunologic Markers in Melanomas: In Silico Analysis
    Yasemin Cakir, Banu Lebe
    Applied Immunohistochemistry & Molecular Morphology.2025; 33(2): 117.     CrossRef
  • Exploration of the regulatory mechanism of norcantharidin on sine oculis homeobox homolog 4 in colon cancer using transcriptome sequencing and bioinformatic
    Fanqin Zhang, Chao Wu, Jingyuan Zhang, Zhihong Huang, Antony Stalin, Yiyan Zhai, Shuqi Liu, Jiarui Wu
    Journal of Traditional Chinese Medical Sciences.2025; 12(2): 259.     CrossRef
  • Immune checkpoint inhibitor (ICI) therapy in central nervous system cancers: State-of-the-art and future outlook
    Roghaye Keshavarz Sadegh, Kiarash Saleki, Nima Rezaei
    International Immunopharmacology.2025; 159: 114837.     CrossRef
  • The Role of Next-Generation Probiotics in Colorectal Cancer Pathways: Mechanisms and Therapeutic Potential
    Sheikh Saba Naz, Josep Sabate Ortega
    Probiotics and Antimicrobial Proteins.2025;[Epub]     CrossRef
  • Clinicopathologic, genetic and immune cell infiltration analysis of colorectal signet ring cell carcinoma with comparison to conventional adenocarcinoma
    Yang An, Jiaolin Zhou, Lan Su, Lin Cong, Xinxin Mao, Bo Chen, Yuhua Gong, Yaping Xu, Han Chen, Chentong Wang, Guole Lin, Huanwen Wu
    Journal of the National Cancer Center.2025;[Epub]     CrossRef
  • Biomarkers to predict efficacy of immune checkpoint inhibitors in colorectal cancer patients: a systematic review and meta-analysis
    Hang Yu, Qingquan Liu, Keting Wu, Shuang Tang
    Clinical and Experimental Medicine.2024;[Epub]     CrossRef
  • An Insight into the Peculiarities of Signet-Ring Cell Carcinoma of the Colon – a Narrative Review
    Loredana Farcaș, Diana Voskuil-Galoș
    Journal of Medical and Radiation Oncology.2024; 4(7): 1.     CrossRef
  • High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma
    Hannah Yang, Beodeul Kang, Yeonjung Ha, Sung Hwan Lee, Ilhwan Kim, Hyeyeong Kim, Won Suk Lee, Gwangil Kim, Sanghoon Jung, Sun Young Rha, Vincent E. Gaillard, Jaekyung Cheon, Chan Kim, Hong Jae Chon
    JHEP Reports.2023; 5(4): 100672.     CrossRef
  • Identification of ZBTB4 as an immunological biomarker that can inhibit the proliferation and invasion of pancreatic cancer
    Zhe Yang, Feiran Chen, Feng Wang, Xiubing Chen, Biaolin Zheng, Xiaomin Liao, Zhejun Deng, Xianxian Ruan, Jing Ning, Qing Li, Haixing Jiang, Shanyu Qin
    BMC Cancer.2023;[Epub]     CrossRef
  • PD-L1 Expression in Colorectal Carcinoma: A Comparison of 3 Scoring Methods in a Cohort of Jordanian Patients
    Heyam A. Awad, Maher A. Sughayer, Jumana M. Obeid, Yaqoot N. Heilat, Ahmad S. Alhesa, Reda M. Yousef, Nabil M. Hasasna, Shafiq A. Masoud, Tareq Saleh
    Applied Immunohistochemistry & Molecular Morphology.2023; 31(6): 379.     CrossRef
  • Systemic Delivery of a STING Agonist‐Loaded Positively Charged Liposome Selectively Targets Tumor Immune Microenvironment and Suppresses Tumor Angiogenesis
    Eun‐Jin Go, Hannah Yang, Wooram Park, Seung Joon Lee, Jun‐Hyeok Han, So Jung Kong, Won Suk Lee, Dong Keun Han, Hong Jae Chon, Chan Kim
    Small.2023;[Epub]     CrossRef
  • Review of the Immune Checkpoint Inhibitors in the Context of Cancer Treatment
    Norah A. Alturki
    Journal of Clinical Medicine.2023; 12(13): 4301.     CrossRef
  • Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives
    Nian-Nian Zhong, Han-Qi Wang, Xin-Yue Huang, Zi-Zhan Li, Lei-Ming Cao, Fang-Yi Huo, Bing Liu, Lin-Lin Bu
    Seminars in Cancer Biology.2023; 95: 52.     CrossRef
  • Artificial intelligence for prediction of response to cancer immunotherapy
    Yuhan Yang, Yunuo Zhao, Xici Liu, Juan Huang
    Seminars in Cancer Biology.2022; 87: 137.     CrossRef
  • 9,370 View
  • 281 Download
  • 10 Web of Science
  • 14 Crossref
Close layer
Prevalence of Psychological Symptoms in Patients Undergoing Pancreatoduodenectomy and Results of a Distress Management System: A Clinic-Based Study
Mee Joo Kang, Eun-Seung Yu, Young Hwa Kang, Hyeong Min Park, Sang-Jae Park, Sun-Whe Kim, Jong-Heun Kim, Sung-Sik Han
Cancer Res Treat. 2022;54(4):1138-1147.   Published online January 4, 2022
DOI: https://doi.org/10.4143/crt.2021.842
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Patients undergoing pancreatoduodenectomy are a high-risk group that requires psychosocial support. This study retrospectively reviewed the prevalence of psychological symptoms in patients undergoing pancreatoduodenectomy for periampullary neoplasm and the psychosocial referral rate after implementing full screening and triage algorithm for administering a distress management protocol based on the integrated supportive care system established in 2010.
Materials and Methods
From September 2010 to December 2018, insomnia, anxiety, and depression were screened on the first day of admission (T1) and on the 10th postoperative day (T2). Patients with clinical levels of distress were referred to a mental health clinic for appropriate aftercare.
Results
The adherence rate to routine screening was 82.7% (364/440). Among the 364 patients, the prevalence of insomnia, anxiety, and depression increased from 22.0% (T1) to 32.6% (T2, p=0.001), 29.1% to 33.6% (p=0.256), and 18.4% to 27.6% (p=0.001), respectively. Less than 45% of those with psychological symptoms expressed their needs for psychological supportive care. Among those with psychological symptoms at T2, clinical insomnia, anxiety, and depression were detected via in-depth evaluations among 77.2%, 38.1%, and 82.5% of patients, respectively. Patients who had two or more symptoms at T2 had a longer postoperative hospital stay, as compared to those with one or no symptoms (a median of 20.5 days vs. 18.0 days, p=0.006). Psychiatric consultation rate was 72.8% among patients with clinical psychological symptoms, and 74% of the consulted patients completed psychiatric intervention before discharge.
Conclusion
Over one-third of the patients had psychological symptoms before and after pancreatoduodenectomy. Implementing a routine psychological symptoms screening with a systematic psychiatric referral protocol enhanced surgeons’ responsiveness to patients’ psychological symptoms.

Citations

Citations to this article as recorded by  
  • Development of a novel rat model for pancreaticoduodenectomy
    Yifei Yang, Zhiang Wang, Neng Tang, Liang Mao, Yudong Qiu, Xu Fu
    Scientific Reports.2025;[Epub]     CrossRef
  • Assessing the long-term priorities of pancreaticoduodenectomy survivors
    Edward A. Joseph, Kara D. Bowers, Rebecca Marcus, Bibek Aryal, Suzanne C. Schiffman, Patrick L. Wagner, Sricharan Chalikonda, David L. Bartlett, Casey J. Allen
    HPB.2024; 26(5): 703.     CrossRef
  • Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol
    Kaili Yu, Zhenguo Song, Bowen Zhang, Qian Pan, Shan Gan, Shaoyong Yang, Quanyong Yang, Xinhua Zuo, Yiqing Yin
    Trials.2023;[Epub]     CrossRef
  • 6,180 View
  • 101 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
Radiofrequency Ablation versus Stereotactic Body Radiation Therapy in the Treatment of Colorectal Cancer Liver Metastases
Jesang Yu, Dong Hwan Kim, Jungbok Lee, Yong Moon Shin, Jong Hoon Kim, Sang Min Yoon, Jinhong Jung, Jin Cheon Kim, Chang Sik Yu, Seok-Byung Lim, In Ja Park, Tae Won Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Jin-hong Park, So Yeon Kim
Cancer Res Treat. 2022;54(3):850-859.   Published online October 13, 2021
DOI: https://doi.org/10.4143/crt.2021.674
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to compare the treatment outcomes of radiofrequency ablation (RFA) and stereotactic body radiation therapy (SBRT) for colorectal cancer liver metastases (CRLM) and to determine the favorable treatment modality according to tumor characteristics.
Materials and Methods
We retrospectively analyzed the records of 222 colorectal cancer patients with 330 CRLM who underwent RFA (268 tumors in 178 patients) or SBRT (62 tumors in 44 patients) between 2007 and 2014. Kaplan–Meier method and Cox models were used by adjusting with inverse probability of treatment weighting (IPTW).
Results
The median follow-up duration was 30.5 months. The median tumor size was significantly smaller in the RFA group than in the SBRT group (1.5 cm vs 2.3 cm, p<0.001). In IPTW-adjusted analysis, difference in treatment modality was not associated with significant differences in 1-year and 3-year recurrence-free survival (35% vs 43%, 22% vs 23%; p=0.198), overall survival (96% vs 91%, 58% vs 56%; p=0.508), and freedom from local progression (FFLP; 90% vs 72%, 78% vs 60%; p=0.106). Significant interaction effect between the treatment modality and tumor size was observed for FFLP (p=0.001). In IPTW-adjusted subgroup analysis of patients with tumor size >2 cm, the SBRT group had a higher FFLP compared with the RFA group (HR, 0.153; p<0.001).
Conclusion
SBRT and RFA showed similar local control in the treatment of patients with CRLM. Tumor size was an independent prognostic factor for local control and SBRT may be preferred for larger tumors.

Citations

Citations to this article as recorded by  
  • Ablative techniques in colorectal liver metastases: A systematic review, descriptive summary of practice, and recommendations for optimal data reporting
    Wee Han Ng, Catarina Machado, Alice Rooney, Robert Jones, Jonathan Rees, Samir Pathak
    European Journal of Surgical Oncology.2025; 51(2): 109487.     CrossRef
  • Effects of maximum dose on local control after stereotactic body radiotherapy for oligometastatic tumors of colorectal cancer
    Su Jin Kang, Jongmoo Park, Gyu-Seog Choi, Jong Gwang Kim, Jun Seok Park, Hye Jin Kim, Jin Ho Baek, Byung Woog Kang, An Na Seo, Shin-Hyung Park, Bong Kyung Bae, Min Kyu Kang, Soo Yeun Park, Devarati Mitra
    PLOS ONE.2025; 20(1): e0313438.     CrossRef
  • Stereotactic ablative radiotherapy (SABR) for liver metastases: where we currently stand
    S.H.R. Kim, M.K. Harrison
    ESMO Gastrointestinal Oncology.2025; 10: 100264.     CrossRef
  • Treatment of Oligometastatic GI Cancers
    Clayton T. Marcinak, Patrick B. Schwartz, Mustafa M. Basree, Newton Hurst, Michael Bassetti, Jeremy D. Kratz, Nataliya V. Uboha
    American Society of Clinical Oncology Educational Book.2024;[Epub]     CrossRef
  • Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations
    D. Pezzulla, G. Chiloiro, E. M. Lima, G. Macchia, C. Romano, S. Reina, G. Panza, S. Cilla, A. G. Morganti, F. Cellini, M. A. Gambacorta, F. Deodato
    Clinical & Experimental Metastasis.2024; 41(5): 667.     CrossRef
  • Interventionelle Therapieoptionen bei oligometastasierten Tumoren
    Max Seidensticker
    Forum.2024; 39(5): 340.     CrossRef
  • Efficacy and safety of B-ultrasound-guided radiofrequency ablation in the treatment of primary liver cancer: Systematic review and meta-analysis
    Xiong Zhang, Hong-Yi Zhu, Ming Yuan
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2986.     CrossRef
  • Analysis of alkaline phosphatase and γ-glutamyltransferase after radiofrequency ablation of primary liver cancer: A retrospective study
    Wen-Yu Huang, Sheng Zheng, Dan Zhu, Ying-Lang Zeng, Juan Yang, Xue-Li Zeng, Pei Liu, Shun-Ling Zhang, Ming Yuan, Zhi-Xia Wang
    World Journal of Gastrointestinal Surgery.2024; 16(9): 2860.     CrossRef
  • Evidence-based clinical recommendations for hypofractionated radiotherapy: exploring efficacy and safety - Part 4: Liver and locally recurrent rectal cancer
    Hwa Kyung Byun, Gyu Sang Yoo, Soo-Yoon Sung, Jin-Ho Song, Byoung Hyuck Kim, Yoo-Kang Kwak, Yeon Joo Kim, Yeon-Sil Kim, Kyung Su Kim
    Radiation Oncology Journal.2024; 42(4): 247.     CrossRef
  • Role of Radiotherapy in Liver Tumors: Recent Update
    Vito Filbert Jayalie, Merinda, Herryanto Lumbantobing, Sudibio, Julius Oentario, Hendriyo, Sry Suryani Widjaja
    Forum of Clinical Oncology.2024; 15(1): 61.     CrossRef
  • Recent trends in radiotherapy use for major cancers in Korea
    Kyungmi Yang, Jeong Eun Lee, Won Park, Yong Chan Ahn, Seung Jae Huh
    Japanese Journal of Clinical Oncology.2023; 53(12): 1177.     CrossRef
  • Combination of endoscopic ultrasound-guided radiofrequency ablation and adaptive radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: A case report
    Federica Borrelli de Andreis, Maria Alessandra Calegari, Angela Romano, Maria Gabriella Brizi, Luigi Sofo, Ivo Boskoski, Guido Costamagna, Fabia Attili
    Current Problems in Cancer: Case Reports.2023; 9: 100216.     CrossRef
  • Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis
    Chai Hong Rim, Jung Sue Lee, Soo Yeon Kim, Jinsil Seong
    JHEP Reports.2023; 5(1): 100594.     CrossRef
  • Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
    Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
    Cancer Research and Treatment.2023; 55(3): 707.     CrossRef
  • Local Control Following Stereotactic Body Radiation Therapy for Liver Oligometastases: Lessons from a Quarter Century
    Sara Mheid, Stefan Allen, Sylvia S. W. Ng, William A. Hall, Nina N. Sanford, Todd A. Aguilera, Ahmed M. Elamir, Rana Bahij, Martijn P. W. Intven, Ganesh Radhakrishna, Issa Mohamad, Jeremy De Leon, Hendrick Tan, Shirley Lewis, Cihan Gani, Teo Stanecu, Vero
    Current Oncology.2023; 30(10): 9230.     CrossRef
  • Combination of endoscopic ultrasound-guided radiofrequency ablation and stereotactic body radiation therapy for the treatment of lymph node metastases from colon adenocarcinoma: a case report
    F. Borrelli de Andreis, M. A. Calegari, A. Romano, M. G. Brizi, L. Sofo, I. Boskoski, G. Costamagna, C. Spada, F. Attili
    Endoscopy.2023; 55(S 02): S86.     CrossRef
  • Evidence on percutaneous radiofrequency and microwave ablation for liver metastases over the last decade
    Koji Tomita, Yusuke Matsui, Mayu Uka, Noriyuki Umakoshi, Takahiro Kawabata, Kazuaki Munetomo, Shoma Nagata, Toshihiro Iguchi, Takao Hiraki
    Japanese Journal of Radiology.2022; 40(10): 1035.     CrossRef
  • 11,199 View
  • 315 Download
  • 14 Web of Science
  • 17 Crossref
Close layer
General
Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era
Kyumin Kim, Harin Kim, Joohee Lee, Inn-Kyu Cho, Myung Hee Ahn, Ki Young Son, Jeong Eun Kim, Hee Jeong Kim, Sang Min Yoon, So Hee Kim, Moon Jung Kwon, Hwa Jung Kim, Su-Jin Koh, Seyoung Seo, Seockhoon Chung
Cancer Res Treat. 2022;54(3):671-679.   Published online September 17, 2021
DOI: https://doi.org/10.4143/crt.2021.585
AbstractAbstract PDFPubReaderePub
Purpose
Literature is scarce regarding cancer care utilization during the massive outbreak of coronavirus disease 2019 (COVID-19) in the Republic of Korea. We investigated functional impairments in mental health and their relationships with depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization among cancer patients in the COVID-19 pandemic era.
Materials and Methods
We used an online survey with questions related to the disturbances faced by patients with cancer in utilizing healthcare services in the pandemic era. Current mental health status was assessed using the Work and Social Adjustment Scale (WSAS), Stress and Anxiety to Viral Epidemics-6 (SAVE-6) scale, Patient Health Questionnaire-9 (PHQ-9), Insomnia Severity Index (ISI), Brief Resilience Scale (BRS), Cancer-Related Dysfunctional Beliefs about Sleep Scale (C-DBS), and Fear of COVID-19 over Cancer (FCC).
Results
Among the 221 responders, 95 (43.0%) reported disruptions in healthcare service utilization during the COVID-19 pandemic. Logistic regression analysis revealed that functional impairment in the mental health of these patients was expected due to disruptions in healthcare service utilization, high levels of depression, anxiety regarding the viral epidemic, fear of COVID over cancer, and low resilience. Mediation analysis showed that patient resilience and cancer-related dysfunctional beliefs about sleep partially mediated the effects of viral anxiety on functional impairment.
Conclusion
In this pandemic era, patients with cancer experience depression, anxiety regarding the viral epidemic, and disruptions in healthcare service utilization, which may influence their functional impairments in mental health.

Citations

Citations to this article as recorded by  
  • The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations
    Amanda L King, Kayla N Roche, Elizabeth Vera, Valentina Pillai, Lily Polskin, Alvina A Acquaye-Mallory, Lisa Boris, Eric Burton, Anna Choi, Ewa Grajkowska, Heather E Leeper, Marissa Panzer, Marta Penas-Prado, Jennifer Reyes, Solmaz Sahebjam, Brett J Theel
    Neuro-Oncology Practice.2025; 12(1): 76.     CrossRef
  • Possible Role of Cancer-Related Dysfunctional Beliefs About Sleep and Intolerance of Uncertainty on Cognitive-Behavioral Model of the COVID-Related Hypochondriasis Among Patients With Cancer
    Harin Kim, Seockhoon Chung
    Psychiatry Investigation.2025; 22(6): 722.     CrossRef
  • Burden of Functional Impairments in Latin American Cancer Survivors
    Ana Carolina Méndez-Silva, Gema Herrera-Belmonte, Vanessa Ucles-Villalobos, Judith del Rosario Bermúdez-Ruiz, Ilse Joadán Santiago-Escamilla, Cecilia Michelle Romo-Aguirre, Humberto Emmanuel Meza-Álvarez, Brenda Espinoza-Castillo
    Current Physical Medicine and Rehabilitation Reports.2025;[Epub]     CrossRef
  • Utilization of upper gastrointestinal tumor inpatient services affected by COVID-19 in China 2018–2021: an interrupted time series analysis
    Xue Yang, Mengying Liu, Hui Lu
    Frontiers in Public Health.2025;[Epub]     CrossRef
  • Prevalence of depressive symptoms and correlates among individuals who self-reported SARS-CoV-2 infection after optimizing the COVID-19 response in China
    Liangjia Wei, Jiao Qin, Zhifeng Lin, Xinju Huang, Jinfeng He, Dee Yu, Fei Zhang, Sisi Li, Ping Cen, Mu Li, Tong Luo, Rongjing Zhang, Shanmei Zhong, Cai Qin, Zeyu Li, Yuan Yang, Huiqi Pan, Mengdi Zhao, Xiaoqiong Wu, Junjun Jiang, Hao Liang, Li Ye, Bingyu L
    Frontiers in Public Health.2024;[Epub]     CrossRef
  • Evaluation of mental health of students in healthcare education programs at Qatar University
    Ola Hayk, Abdulla Mansoor, Shahd Al-Najdi, Alaa Daud, Rula Shami, Najah Al-Hashimi, Kamran Ali
    MedEdPublish.2024; 14: 37.     CrossRef
  • Inpatient Hospice Care in Korea during the COVID-19 Pandemic: A Preliminary Study
    Youn Seon Choi, Sun Wook Hwang, In Cheol Hwang
    Journal of Hospice and Palliative Care.2024; 27(2): 82.     CrossRef
  • Risk factors for heightened COVID‐19‐Related anxiety among breast cancer patients
    Yash B. Shah, Stephanie Kjelstrom, Diana Martinez, Adam Leitenberger, Donna‐Marie Manasseh, Melissa Bollmann‐Jenkins, Ann Partridge, Virginia Kaklamani, Rowen Chlebowski, Sharon Larson, Marisa Weiss
    Cancer Medicine.2023; 12(3): 3577.     CrossRef
  • Discrepancy between desired time in bed and desired total sleep time in patients with cancer: The DBST index and its relationship with insomnia severity and sleep onset latency
    Eulah Cho, Jaeeun Song, Joohee Lee, Inn-Kyu Cho, Dongin Lee, Hayun Choi, Harin Kim, Seockhoon Chung
    Frontiers in Psychiatry.2023;[Epub]     CrossRef
  • Health-related quality of life and depressive symptoms of patients with chronic diseases and the general population before and during the COVID-19 pandemic in Korea
    Yeeun Park, Kyong Park
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • A study of COVID anxiety, spiritual well-being and resilience levels in patients with cancer undergoing chemotherapy during the COVID-19 pandemic: a cross-sectional study in the south of Iran
    Zahra Khiyali, Zeinab Naderi, Mohammadkazem Vakil, Hajar Ghasemi, Azizallah Dehghan, Mostafa Bijani
    BMC Psychology.2023;[Epub]     CrossRef
  • Does Viral Anxiety Influence the Insomnia Severity Among Patients With Insomnia Disorder During COVID-19 Pandemic?
    Jana Sleiman, Eulah Cho, Dongin Lee, Inn-Kyu Cho, Seockhoon Chung, Omer Faruk Uygur
    Sleep Medicine Research.2023; 14(1): 25.     CrossRef
  • Associations of psychological status and ultrasonic characteristics of thyroid nodules in adults during the COVID-19 pandemic
    Zhengwu Lei, Zhongxiang He, Ying Mei, Xiaoya Qi, Pingping Yu, Guoqiong Xu, Hongfeng Cheng, Ruixue Bai, Jing Deng
    Frontiers in Psychology.2023;[Epub]     CrossRef
  • The Impact of COVID-19 on Psychiatric Health in the Korean Population
    Sheng-Min Wang, Sung-Hwan Kim, Won-Seok Choi, Hyun Kook Lim, Young Sup Woo, Chi-Un Pae, Won-Myong Bahk
    Clinical Psychopharmacology and Neuroscience.2023; 21(3): 410.     CrossRef
  • Adherence to Physical Distancing and Health Beliefs About COVID-19 Among Patients With Cancer
    Sajida Fawaz Hammoudi, Oli Ahmed, Hoyoung An, Youjin Hong, Myung Hee Ahn, Seockhoon Chung
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • Catastrophizing Maladaptive Coping Affects the Association Between Viral Anxiety and Fear of Progression in Cancer Patients During COVID-19 Pandemic
    Hyuk Joo Lee, Cheolkyung Sin, Hyeyeong Kim, Hyeon-Su Im, Jae-Cheol Jo, Yoo Jin Lee, Youjin Kim, Junseok Ahn, Soyoung Yoo, Su-Jin Koh, Seockhoon Chung
    Psychiatry Investigation.2023; 20(12): 1204.     CrossRef
  • The role of social support and resilience in the mental health impact of the COVID-19 pandemic among healthcare workers in Spain
    Esther Ortiz-Calvo, Gonzalo Martínez-Alés, Roberto Mediavilla, Elisabeth González-Gómez, Eduardo Fernández-Jiménez, María-Fe Bravo-Ortiz, Berta Moreno-Küstner
    Journal of Psychiatric Research.2022; 148: 181.     CrossRef
  • The Validation Study of the Stress and Anxiety to Viral Epidemics−6 Scale Among Patients With Cancer in the COVID-19 Pandemic
    Hyeyeong Kim, Harin Kim, Hyuk Joo Lee, Eulah Cho, Su-Jin Koh, Oli Ahmed, Seockhoon Chung
    Frontiers in Psychiatry.2022;[Epub]     CrossRef
  • Resilience, Social Support, and Anxious Preoccupation in Patients with Advanced Cancer during COVID-19 Pandemic
    Veronica Velasco-Durantez, Paula Jimenez-Fonseca, Carla M. Martín Abreu, Ismael Ghanem, Manuel González Moya, Elena Asensio, María J. Corral, Adan Rodriguez-Gonzalez, Mireia Gil-Raga, Alberto Carmona-Bayonas, Caterina Calderon
    Cancer Investigation.2022; 40(6): 475.     CrossRef
  • Mental Health in Postoperative Thyroid Patients During the COVID-19 Pandemic
    Shijie Yang, Xiequn Xu
    Frontiers in Endocrinology.2022;[Epub]     CrossRef
  • Effect of Cancer-Related Dysfunctional Beliefs About Sleep on Fear of Cancer Progression in the Coronavirus Pandemic
    Harin Kim, Inn-Kyu Cho, Dongin Lee, Kyumin Kim, Joohee Lee, Eulah Cho, C. Hyung Keun Park, Seockhoon Chung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Insomnia Mediate the Influence of Reassurance-Seeking Behavior and Viral Anxiety on Preoccupation With COVID-19 Among the General Population
    Eulah Cho, Dongin Lee, Inn-Kyu Cho, Joohee Lee, Junseok Ahn, Young Rong Bang
    Sleep Medicine Research.2022; 13(2): 68.     CrossRef
  • Reliability and Validity of Dysfunctional Beliefs About Sleep-2 (DBS-2), an Ultra-brief Rating Scale for Assessing Dysfunctional Thoughts About Sleep
    Kyumin Kim, Seockhoon Chung, Eulah Cho, Jung Mun Choi, Dongin Lee, Inn-Kyu Cho
    Sleep Medicine Research.2022; 13(3): 165.     CrossRef
  • 11,893 View
  • 282 Download
  • 22 Web of Science
  • 23 Crossref
Close layer
Sarcoma
Clinicopathologic Characteristics and Clinical Outcome of Localized Liposarcoma: A Single-Center Experience over 25 Years and Evaluation of PD-L1 Expression
Heejung Chae, Jeong Eun Kim, Wanlim Kim, Jong-Seok Lee, Si Yeol Song, Min Hee Lee, Hye Won Chung, Kyung-Ja Cho, Joon Seon Song, Jin-Hee Ahn
Cancer Res Treat. 2022;54(2):579-589.   Published online July 6, 2021
DOI: https://doi.org/10.4143/crt.2021.496
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
For liposarcoma (LPS), clinical course and proper treatment strategies have not been well-established. Recently, immune-checkpoint inhibitors have shown potential efficacy in LPS. We aimed to describe the clinical course of LPS and evaluate the clinical impact of programmed death-ligand 1 (PD-L1).
Materials and Methods
We reviewed all consecutive patients (n=332) who underwent curative-intent surgery for localized LPS at Asan Medical Center between 1989 and 2017. PD-L1 testing was performed in well-differentiated and dedifferentiated LPS.
Results
The median age was 56 years with males comprising 60.8%. Abdomen-pelvis (47.6%) and well-differentiated (37.7%) were the most frequent primary site and histologic subtype, respectively. During a median follow-up of 81.2 months, recurrence was observed in 135 (40.7%), and 86.7% (117/135) were loco-regional. Well-differentiated subtype (hazard ratio [HR], 0.38), abdomen-pelvis origin (HR, 2.43), tumor size larger than 5 cm (HR, 1.83), positive resection margin (HR, 2.58), and postoperative radiotherapy (HR, 0.36) were significantly related with recurrence-free survival as well as visceral involvement (HR, 1.84) and multifocality (HR, 3.79) in abdomen-pelvis LPS. PD-L1 was positive in 31.5% (23/73) and 51.3% (39/76) of well-differentiated and dedifferentiated LPS, respectively, but had no impact on survival outcomes.
Conclusion
Clinical course of LPS was heterogeneous according to histology and anatomic location. Clear resection margin was important to lower recurrence and postoperative radiotherapy might have additional benefit. A decent portion of well-differentiated and dedifferentiated LPS were positive for PD-L1, but its prognostic role was unclear. Further research is needed to determine clinical implications of PD-L1, especially for advanced-stage LPS with unmet needs for effective systemic treatment.

Citations

Citations to this article as recorded by  
  • Recurrent Intrathoracic Liposarcoma: A Case Report and a Comprehensive Literature Review of a Rare Clinical Entity
    Vasileios Leivaditis , Manfred Dahm , Athanasios Papatriantafyllou, Hans-Georg Keul, Lydia Kohl, Hans-Joachim Schäfers
    Cureus.2024;[Epub]     CrossRef
  • Clinicopathological Features of Intrathoracic Liposarcoma—A Systematic Review with an Illustrative Case
    Kajetan Kiełbowski, Nikola Ruszel, Seweryn Adam Skrzyniarz, Małgorzata Edyta Wojtyś, Rafał Becht, Konrad Ptaszyński, Darko Gajić, Janusz Wójcik
    Journal of Clinical Medicine.2022; 11(24): 7353.     CrossRef
  • 7,453 View
  • 119 Download
  • 1 Web of Science
  • 2 Crossref
Close layer
Breast cancer
Comparison of the Effectiveness and Clinical Outcome of Everolimus Followed by CDK4/6 Inhibitors with the Opposite Treatment Sequence in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Hyehyun Jeong, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Cancer Res Treat. 2022;54(2):469-477.   Published online June 23, 2021
DOI: https://doi.org/10.4143/crt.2021.205
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In hormone receptor-positive, human epidermal growth factor receptor 2–negative metastatic breast cancer (HR+ HER2–MBC), the mainstay treatment options include cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and everolimus (EVE) in combination with endocrine treatment. This study aims to compare the outcomes of the following treatment sequences: CDK4/6i followed by EVE and EVE followed by CDK4/6i.
Materials and Methods
Data from HR+ HER2– MBC patients treated between January 2014 and November 2020 with both CDK4/6i and EVE were retrospectively analyzed.
Results
Among the 88 patients included in the study, 51 received CDK4/6i before EVE (C→E group), and 37 received EVE before CDK4/6i (E→C group) with endocrine treatment. More patients in the E→C group had endocrine resistance (13.7% vs. 40.5%), experienced palliative chemotherapy (7.8% vs. 40.5%), and were heavily treated (treated as ≥ 3rd line, 5.9% vs. 40.5%). Median overall survival was 46.8 months in the C→E group and 38.9 months in the E→C group (p=0.151). Median composite progression-free survival (PFS), defined as the time from the start of the preceding regimen to disease progression on the following regimen or death, was 24.8 months in the C→E group vs. 21.8 months in the E→C group (p=0.681). Median PFS2/PFS1 ratio did not differ significantly between groups (0.5 in the C→E group, 0.6 in the E→C group; p=0.775). Ten patients (11.4%) discontinued EVE, and two patients (2.3%) discontinued CDK4/6i during treatment.
Conclusion
Although the CDK4/6i-based regimen should be considered as an earlier line of treatment, CDK4/6i- and EVE-based treatments can be valid options in circumstances where the other treatment had been already given.

Citations

Citations to this article as recorded by  
  • CDK4/6 inhibitors for metastatic breast cancer in routine clinical practice in Spain: survey of patterns of use and oncologists’ perceptions
    F. Moreno, V. Iranzo, I. Álvarez, A. Antón, J. I. Chacón, J. Gavilá, M. Martín, P. Sánchez Rovira, P. Gratal, M. J. Fernández González, R. López
    Clinical and Translational Oncology.2025; 27(9): 3819.     CrossRef
  • The Growth Modulation Index (GMI) as an Efficacy Outcome in Cancer Clinical Trials: A Scoping Review with Suggested Reporting Guidelines
    Kilian Trin, Cynthia Dalleau, Simone Mathoulin-Pelissier, Christophe Le Tourneau, Derek Dinart, Carine Bellera
    Current Oncology Reports.2025; 27(5): 516.     CrossRef
  • The different sequences of CDK4/6 inhibitor and mTOR inhibitor in HR+/HER2-advanced breast cancer: A multicenter real-world study
    Yuqian Liao, Yujing Tan, Yipeng Li, Fei Ma, Jiayu Wang, Pin Zhang, Qing Li, Qiao Li, Yang Luo, Bo Lan, Shanshan Chen, Binghe Xu, Hanfang Jiang, Weihong Zhao, Ying Fan
    Heliyon.2024; 10(19): e38147.     CrossRef
  • Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study
    Hélène François-Martin, Audrey Lardy-Cléaud, Barbara Pistilli, Christelle Levy, Véronique Diéras, Jean-Sébastien Frenel, Séverine Guiu, Marie-Ange Mouret-Reynier, Audrey Mailliez, Jean-Christophe Eymard, Thierry Petit, Mony Ung, Isabelle Desmoulins, Paule
    Cancers.2023; 15(4): 1191.     CrossRef
  • Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells
    Mikhail V. Blagosklonny
    Oncotarget.2023; 14(1): 193.     CrossRef
  • A systematic review of computational approaches to understand cancer biology for informed drug repurposing
    Faheem Ahmed, Anupama Samantasinghar, Afaque Manzoor Soomro, Sejong Kim, Kyung Hyun Choi
    Journal of Biomedical Informatics.2023; 142: 104373.     CrossRef
  • Tetraspanin 1 (TSPAN1) promotes growth and transferation of breast cancer cells via mediating PI3K/Akt pathway
    Yange Wu, Wenxiu Chen, Yufeng Gong, Hongxia Liu, Bo Zhang
    Bioengineered.2021; 12(2): 10761.     CrossRef
  • 8,413 View
  • 223 Download
  • 8 Web of Science
  • 7 Crossref
Close layer
Special Articles
Life-Sustaining Treatment States in Korean Cancer Patients after Enforcement of Act on Decisions on Life-Sustaining Treatment for Patients at the End of Life
Young-Woong Won, Hwa Jung Kim, Jung Hye Kwon, Ha Yeon Lee, Sun Kyung Baek, Yu Jung Kim, Do Yeun Kim, Hyewon Ryu
Cancer Res Treat. 2021;53(4):908-916.   Published online June 2, 2021
DOI: https://doi.org/10.4143/crt.2021.325
AbstractAbstract PDFPubReaderePub
Purpose
In Korea, the “Act on Hospice and Palliative Care and Decisions on Life-sustaining Treatment for Patients at the End of Life” was enacted on February 4, 2018. This study was conducted to analyze the current state of life-sustaining treatment decisions based on National Health Insurance Service (NHIS) data after the law came into force.
Materials and Methods
The data of 173,028 cancer deaths were extracted from NHIS qualification data between November 2015 and January 2019.
Results
The number of cancer deaths complied with the law process was 14,438 of 54,635 cases (26.4%). The rate of patient self-determination was 49.0%. The patients complying with the law process have used a hospice center more frequently (28% vs. 14%). However, the rate of intensive care unit (ICU) admission was similar between the patients who complied with and without the law process (ICU admission, 23% vs. 21%). There was no difference in the proportion of patients who had undergone mechanical ventilation and hemodialysis in the comparative analysis before and after the enforcement of the law and the analysis according to the compliance with the law. The patients who complied with the law process received cardiopulmonary resuscitation at a lower rate.
Conclusion
The law has positive effects on the rate of life-sustaining treatment decision by patient’s determination. However, there was no sufficient effect on the withholding or withdrawing of life-sustaining treatment, which could protect the patient from unnecessary or harmful interventions.

Citations

Citations to this article as recorded by  
  • Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
    Yoon Jung Jang, Yun Jung Yang, Hoi Jung Koo, Hye Won Yoon, Seongbeom Uhm, Sun Young Kim, Jeong Eun Kim, Jin Won Huh, Tae Won Kim, Seyoung Seo
    Cancer Research and Treatment.2025; 57(1): 280.     CrossRef
  • The Impact of Advanced Care Planning on Hospice Utilization in Patients with Cancer: A Nationwide Analysis in Korea
    Woorim Kim, Boram Kim, Minju Kim, Jin Young Choi
    Cancers.2025; 17(9): 1471.     CrossRef
  • The impact of withholding and withdrawal life-sustaining treatment issues on patients with sepsis: a prospective, nationwide, multicenter cohort study
    So-yun Kim, Da Hyun Kang, Hyekyeong Ju, Dong Kyu Oh, Su Yeon Lee, Mi Hyeon Park, Chae-Man Lim, Song I Lee, Chae-Man Lim, Sang-Bum Hong, Dong Kyu Oh, Su Yeon Lee, Gee Young Suh, Kyeongman Jeon, Ryoung-Eun Ko, Young-Jae Cho, Yeon Joo Lee, Sung Yoon Lim, Sun
    Scientific Reports.2025;[Epub]     CrossRef
  • Long‐Term Outcomes and Predictors in Cancer‐Related Stroke Using the Linked Data Set
    Tae Jung Kim, Ji Sung Lee, Mi Sun Oh, Soo‐Hyun Park, Kyung‐Ho Yu, Byung‐Chul Lee, Byung‐Woo Yoon, Sang‐Bae Ko
    Journal of the American Heart Association.2025;[Epub]     CrossRef
  • Characteristics and outcomes of patients with do-not-resuscitate and physician orders for life-sustaining treatment in a medical intensive care unit: a retrospective cohort study
    Song-I Lee, Ye-Rin Ju, Da Hyun Kang, Jeong Eun Lee
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
    Jiyeon Choi, Heejung Jeon, Ilhak Lee
    Asian Bioethics Review.2024; 16(1): 33.     CrossRef
  • Recent Trends in the Withdrawal of Life-Sustaining Treatment in Patients with Acute Cerebrovascular Disease : 2017–2021
    Seung Hwan Kim, Ji Hwan Jang, Young Zoon Kim, Kyu Hong Kim, Taek Min Nam
    Journal of Korean Neurosurgical Society.2024; 67(1): 73.     CrossRef
  • The Impact of Withdrawing or Withholding of Life-Sustaining Treatment: A Nationwide Case-Control Study Based on Medical Cost Analysis
    Claire Junga Kim, Do-Kyong Kim, Sookyeong Mun, Minkook Son
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • For the Universal Right to Access Quality End-of-Life Care in Korea: Broadening Our Perspective After the 2018 Life-Sustaining Treatment Decisions Act
    Hye Yoon Park, Min Sun Kim, Shin Hye Yoo, Jung Lee, In Gyu Song, So Yeon Jeon, Eun Kyung Choi
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Differences in end-of-life care patterns between types of hospice used for cancer patients: a retrospective cohort study
    Il Yun, Eun-Cheol Park, Chung Mo Nam, Jaeyong Shin, Suk-Yong Jang, Sung-In Jang
    BMC Palliative Care.2024;[Epub]     CrossRef
  • Epidemiology of patients who died in the emergency departments and need of end-of-life care in Korea from 2016 to 2019
    Sun Young Lee, Young Sun Ro, Sang Do Shin, Eunsil Ko, Seong Jung Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • Use of high‐flow nasal cannula oxygen therapy for patients with terminal cancer at the end of life
    Jung Sun Kim, Jeongmi Shin, Nam Hee Kim, Sun Young Lee, Shin Hye Yoo, Bhumsuk Keam, Dae Seog Heo
    Cancer Medicine.2023; 12(13): 14612.     CrossRef
  • Preferred versus Actual Place of Care and Factors Associated with Home Discharge among Korean Patients with Advanced Cancer: A Retrospective Cohort Study
    In Young Hwang, Yohan Han, Min Sun Kim, Kyae Hyung Kim, Belong Cho, Wonho Choi, Yejin Kim, Shin Hye Yoo, Sun Young Lee
    Healthcare.2023; 11(13): 1939.     CrossRef
  • Healthcare resource utilization and medical costs in patients with terminal cancer during best supportive care
    Dong-Won Kang, Yoon-Bo Shim, Eui-Kyung Lee, Mi-Hai Park, Wen-Chi Chou
    PLOS ONE.2022; 17(6): e0269565.     CrossRef
  • Aggressiveness of care in the last days of life in the emergency department of a tertiary hospital in Korea
    Jung Sun Kim, Sun Young Lee, Min Sung Lee, Shin Hye Yoo, Jeongmi Shin, Wonho Choi, Yejin Kim, Hyung Sook Han, Jinui Hong, Bhumsuk Keam, Dae Seog Heo
    BMC Palliative Care.2022;[Epub]     CrossRef
  • Effect of life-sustaining treatment decision law on pediatric in-hospital cardiopulmonary resuscitation rate: A Korean population-based study
    Jaeyoung Choi, Ah Young Choi, Esther Park, Meong Hi Son, Joongbum Cho
    Resuscitation.2022; 180: 38.     CrossRef
  • Association of perceived life satisfaction with attitudes toward life-sustaining treatment among the elderly in South Korea: a cross-sectional study
    Il Yun, Hyunkyu Kim, Eun-Cheol Park, Suk-Yong Jang
    BMC Palliative Care.2022;[Epub]     CrossRef
  • Willingness of patients with cancer pain to participate in end-of-life decisions: a multi-center cross-sectional study from three coastal provinces in southern China
    Xi Ke, Hongyu Zhu, Yu Zhang, Ling Yang, Simei Shi, Fang Zhu, Huiyu Luo
    BMC Palliative Care.2022;[Epub]     CrossRef
  • The Law Changes Behaviors: Is It Just Enough?
    Dae Ho Lee
    Cancer Research and Treatment.2021; 53(4): 895.     CrossRef
  • 8,464 View
  • 168 Download
  • 19 Web of Science
  • 19 Crossref
Close layer
Current Status and Cardinal Features of Patient Autonomy after Enactment of the Life-Sustaining Treatment Decisions Act in Korea
Hwa Jung Kim, Yu Jung Kim, Jung Hye Kwon, Young-Woong Won, Ha Yeon Lee, Sun Kyung Baek, Hyewon Ryu, Do Yeun Kim
Cancer Res Treat. 2021;53(4):917-925.   Published online June 2, 2021
DOI: https://doi.org/10.4143/crt.2021.324
AbstractAbstract PDFPubReaderePub
Purpose
The main purpose of the Life-Sustaining Treatment Decisions Act recently enacted in Korea is to respect the patient’s self-determination. We aimed to investigate the current status and features of patient self-determination after implementation of the law.
Materials and Methods
Between February 2018 and January 2019, 54,635 cancer deaths were identified from the National Health Insurance Service (NHIS) database. We analyzed the characteristics of decedents who complied with the law process by self-determination compared with decedents with family determination and with decedents who did not comply with the law process.
Results
In multivariable analysis, patients with self-determination were younger, were less likely to live in rural areas, were less likely to belong to the highest income quintile, were less likely to be treated in general hospitals, and were more likely to show a longer time from cancer diagnosis compared with patients with family determination. Compared with patients who did not comply with the law process, patients with self-determination were younger, lived in Seoul or capital area, were less likely to belong to the highest income quintile, were treated in general hospitals, were less likely to have genitourinary or hematologic malignancies, scored higher on the Charlson comorbidity index, and showed a longer time from cancer diagnosis. Patients with self-determination were more likely to use hospice and less likely to use intensive care units (ICUs) at the end-of-life (EOL).
Conclusion
Decedents with self-determination were more likely to be younger, reside in the Seoul or capital area, show a longer time from cancer diagnosis, and were less likely to belong to the highest income quintile. They utilized hospice more frequently, and received less ICU care at the EOL.

Citations

Citations to this article as recorded by  
  • The Impact of Advanced Care Planning on Hospice Utilization in Patients with Cancer: A Nationwide Analysis in Korea
    Woorim Kim, Boram Kim, Minju Kim, Jin Young Choi
    Cancers.2025; 17(9): 1471.     CrossRef
  • ED Visits Among Patients With Advanced Cancer Referred to Outpatient Palliative Care
    Ye Sul Jeung, Sung A. Bae, Sun Young Lee, Jin-Ah Sim, Bhumsuk Keam, Shin Hye Yoo
    JAMA Network Open.2025; 8(7): e2521101.     CrossRef
  • Surgical Decision-Making Experience of Patients with Lumbar Disc Herniation: A Qualitative Study
    Mingyang Qian, Wei Jiang, Qingsong Zou, Wenlin Cheng, Mengyi Xu, Li Hua, Jiangming Yu
    Patient Preference and Adherence.2025; Volume 19: 2609.     CrossRef
  • Factors influencing self-decision in withholding or withdrawal of life-sustaining treatments among older patients admitted to general hospital: A retrospective case-control study
    Young Min Jeong, Hee-Ju Kim
    Journal of Korean Gerontological Nursing.2025; 27(3): 271.     CrossRef
  • The effects of hospice care on healthcare expenditure among cancer patients
    Hoyol Jhang, Wonjeong Jeong, Hyun-Soo Zhang, Dong-Woo Choi, Hyejung Kang, Sohee Park
    BMC Health Services Research.2023;[Epub]     CrossRef
  • Problems Related to the Act on Decisions on Life-Sustaining Treatment and Directions for Improvement
    Dae Seog Heo, Shin Hye Yoo, Bhumsuk Keam, Sang Ho Yoo, Younsuck Koh
    The Korean Journal of Hospice and Palliative Care.2022; 25(1): 1.     CrossRef
  • Aggressiveness of care in the last days of life in the emergency department of a tertiary hospital in Korea
    Jung Sun Kim, Sun Young Lee, Min Sung Lee, Shin Hye Yoo, Jeongmi Shin, Wonho Choi, Yejin Kim, Hyung Sook Han, Jinui Hong, Bhumsuk Keam, Dae Seog Heo
    BMC Palliative Care.2022;[Epub]     CrossRef
  • Use of antimicrobial agents in actively dying inpatients after suspension of life-sustaining treatments: Suggestion for antimicrobial stewardship
    Dayeong Kim, Subin Kim, Kyoung Hwa Lee, Sang Hoon Han
    Journal of Microbiology, Immunology and Infection.2022; 55(4): 651.     CrossRef
  • Association of perceived life satisfaction with attitudes toward life-sustaining treatment among the elderly in South Korea: a cross-sectional study
    Il Yun, Hyunkyu Kim, Eun-Cheol Park, Suk-Yong Jang
    BMC Palliative Care.2022;[Epub]     CrossRef
  • The Law Changes Behaviors: Is It Just Enough?
    Dae Ho Lee
    Cancer Research and Treatment.2021; 53(4): 895.     CrossRef
  • 8,185 View
  • 146 Download
  • 7 Web of Science
  • 10 Crossref
Close layer
Original Articles
CNS cancer
Detection of TERT Promoter Mutations Using Targeted Next-Generation Sequencing: Overcoming GC Bias through Trial and Error
Hyunwoo Lee, Boram Lee, Deok Geun Kim, Yoon Ah Cho, Jung-Sun Kim, Yeon-Lim Suh
Cancer Res Treat. 2022;54(1):75-83.   Published online May 3, 2021
DOI: https://doi.org/10.4143/crt.2021.107
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Detection of telomerase reverse transcriptase (TERT) promoter mutations is a crucial process in the integrated diagnosis of glioblastomas. However, the TERT promoter region is difficult to amplify because of its high guanine-cytosine (GC) content (> 80%). This study aimed to analyze the capturing of TERT mutations by targeted next-generation sequencing (NGS) using formalin-fixed paraffin-embedded tissues.
Materials and Methods
We compared the detection rate of TERT mutations between targeted NGS and Sanger sequencing in 25 cases of isocitrate dehydrgenase (IDH)-wildtype glioblastomas and 10 cases of non-neoplastic gastric tissues. Our customized panel consisted of 232 essential glioma-associated genes.
Results
Sanger sequencing detected TERT mutations in 17 out of 25 glioblastomas, but all TERT mutations were missed by targeted NGS. After the manual visualization of the NGS data using an integrative genomics viewer, 16 cases showed a TERT mutation with a very low read depth (mean, 21.59; median, 25), which revealed false-negative results using auto-filtering. We optimized our customized panel by extending the length of oligonucleotide baits and increasing the number of baits spanning the coverage of the TERT promoter, which did not amplify well due to the high GC content.
Conclusion
Our study confirmed that it is crucial to consider the recognition of molecular bias and to carefully interpret NGS data.

Citations

Citations to this article as recorded by  
  • Modernizing Neuro-Oncology: The Impact of Imaging, Liquid Biopsies, and AI on Diagnosis and Treatment
    John Rafanan, Nabih Ghani, Sarah Kazemeini, Ahmed Nadeem-Tariq, Ryan Shih, Thomas A. Vida
    International Journal of Molecular Sciences.2025; 26(3): 917.     CrossRef
  • A Concordance Study among 26 NGS Laboratories Participating in the NCI Molecular Analysis for Therapy Choice Clinical Trial
    Linda K. Zane, Laura M. Yee, Ting-Chia Chang, Jeffrey Sklar, Guangxiao Yang, Jia Di Wen, Peining Li, Robin Harrington, David J. Sims, Kneshay Harper, Jeffrey M. Trent, Janine R. LoBello, Szabolcs Szelinger, Kasey Benson, Jia Zeng, Kelsey Poorman, Danbin X
    Clinical Cancer Research.2025; 31(16): 3512.     CrossRef
  • Quality metrics for enhanced performance of an NGS panel using single-vial amplification technology
    Subit Barua, Susan Hsiao, Emily Clancy, Christopher Freeman, Mahesh Mansukhani, Helen Fernandes
    Journal of Clinical Pathology.2024; 77(1): 46.     CrossRef
  • Diagnostic utility of genetic alterations in distinguishing IDH‐wildtype glioblastoma from lower‐grade gliomas: Insight from next‐generation sequencing analysis of 479 cases
    Boram Lee, Soohyun Hwang, Hyunsik Bae, Kyue‐Hee Choi, Yeon‐Lim Suh
    Brain Pathology.2024;[Epub]     CrossRef
  • Novel method for detecting frequent TERT promoter hot spot mutations in bladder cancer samples
    Ákos Kovács, Farkas Sükösd, Levente Kuthi, Imre M. Boros, Balázs Vedelek
    Clinical and Experimental Medicine.2024;[Epub]     CrossRef
  • Changes in Mutations of Cell-Free DNA and Liver Tumor Tissue in Patients with Advanced Hepatocellular Carcinoma before and after Introduction of Lenvatinib
    Mio Tsuruoka, Masashi Ninomiya, Jun Inoue, Tomoaki Iwata, Akitoshi Sano, Kosuke Sato, Masazumi Onuki, Satoko Sawahashi, Atsushi Masamune
    Oncology.2024; 102(12): 1072.     CrossRef
  • Melanoma genomics – will we go beyond BRAF in clinics?
    Justyna Mirek, Wiesław Bal, Magdalena Olbryt
    Journal of Cancer Research and Clinical Oncology.2024;[Epub]     CrossRef
  • Deep Learning Prediction of TERT Promoter Mutation Status in Thyroid Cancer Using Histologic Images
    Jinhee Kim, Seokhwan Ko, Moonsik Kim, Nora Jee-Young Park, Hyungsoo Han, Junghwan Cho, Ji Young Park
    Medicina.2023; 59(3): 536.     CrossRef
  • Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules
    Guodong Fu, Ronald S. Chazen, Eric Monteiro, Allan Vescan, Jeremy L. Freeman, Ian J. Witterick, Christina MacMillan
    JAMA Network Open.2023; 6(7): e2323500.     CrossRef
  • Molecular Biomarkers and Recent Liquid Biopsy Testing Progress: A Review of the Application of Biosensors for the Diagnosis of Gliomas
    Yuanbin Wu, Xuning Wang, Meng Zhang, Dongdong Wu
    Molecules.2023; 28(15): 5660.     CrossRef
  • Novel, clinically relevant genomic patterns identified by comprehensive genomic profiling in ATRX-deficient IDH-wildtype adult high-grade gliomas
    Gábor Bedics, Péter Szőke, Bence Bátai, Tibor Nagy, Gergő Papp, Noémi Kránitz, Hajnalka Rajnai, Lilla Reiniger, Csaba Bödör, Bálint Scheich
    Scientific Reports.2023;[Epub]     CrossRef
  • 8,908 View
  • 220 Download
  • 12 Web of Science
  • 11 Crossref
Close layer
General
Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea
Dalyong Kim, Shin Hye Yoo, Seyoung Seo, Hyun Jung Lee, Min Sun Kim, Sung Joon Shin, Chi-Yeon Lim, Do Yeun Kim, Dae Seog Heo, Chae-Man Lim
Cancer Res Treat. 2022;54(1):20-29.   Published online April 12, 2021
DOI: https://doi.org/10.4143/crt.2021.131
AbstractAbstract PDFPubReaderePub
Purpose
This study aimed to confirm the decision-making patterns for life-sustaining treatment (LST) and analyze medical service utilization changes after enforcement of the Life-Sustaining Treatment Decision-Making Act.
Materials and Methods
Of 1,237 patients who completed legal forms for life-sustaining treatment (hereafter called the LST form) at three academic hospitals and died at the same institutions, 1,018 cancer patients were included. Medical service utilization and costs were analyzed using claims data.
Results
The median time to death from completion of the LST form was three days (range, 0 to 248 days). Of these, 517 people died within two days of completing the document, and 36.1% of all patients prepared the LST form themselves. The frequency of use of the intensive care unit, continuous renal replacement therapy, and mechanical ventilation was significantly higher when the families filled out the form without knowing the patient’s intention. In the top 10% of the medical expense groups, the decision-makers for LST were family members rather than patients (28% patients vs. 32% family members who knew and 40% family members who did not know the patient’s intention).
Conclusion
The cancer patient’s own decision-making rather than the family’s decision was associated with earlier decision-making, less use of some critical treatments (except chemotherapy) and expensive evaluations, and a trend toward lower medical costs.

Citations

Citations to this article as recorded by  
  • Nurses' engagement in advance care planning practices: A descriptive cross‐sectional study
    Sangmin Lee, Naixue Cui, Hyejin Kim
    Journal of Clinical Nursing.2025; 34(6): 2149.     CrossRef
  • Factors Affecting Life-Sustaining Treatment Decisions and Changes in Clinical Practice after Enforcement of the Life-Sustaining Treatment (LST) Decision Act: A Tertiary Hospital Experience in Korea
    Yoon Jung Jang, Yun Jung Yang, Hoi Jung Koo, Hye Won Yoon, Seongbeom Uhm, Sun Young Kim, Jeong Eun Kim, Jin Won Huh, Tae Won Kim, Seyoung Seo
    Cancer Research and Treatment.2025; 57(1): 280.     CrossRef
  • The Impact of Advanced Care Planning on Hospice Utilization in Patients with Cancer: A Nationwide Analysis in Korea
    Woorim Kim, Boram Kim, Minju Kim, Jin Young Choi
    Cancers.2025; 17(9): 1471.     CrossRef
  • Translation, Cultural Adaptation and Validation of the Advance Care Planning Engagement Survey for Korean Older People
    Minjeong Jo, Heejin Chung, Mihyun Park
    International Journal of Older People Nursing.2025;[Epub]     CrossRef
  • Enhanced Outcomes of Training Home Care Nurses to Lead Advance Care Planning for Older Adults
    Heejin Chung, Minjeong Jo, Ji Yeon Choi, Mihyun Park
    Advances in Nursing Science.2025;[Epub]     CrossRef
  • Characteristics of Life-Sustaining Treatment Decisions: National Data Analysis in South Korea
    Jiyeon Choi, Heejung Jeon, Ilhak Lee
    Asian Bioethics Review.2024; 16(1): 33.     CrossRef
  • Characteristics and outcomes of patients with do-not-resuscitate and physician orders for life-sustaining treatment in a medical intensive care unit: a retrospective cohort study
    Song-I Lee, Ye-Rin Ju, Da Hyun Kang, Jeong Eun Lee
    BMC Palliative Care.2024;[Epub]     CrossRef
  • For the Universal Right to Access Quality End-of-Life Care in Korea: Broadening Our Perspective After the 2018 Life-Sustaining Treatment Decisions Act
    Hye Yoon Park, Min Sun Kim, Shin Hye Yoo, Jung Lee, In Gyu Song, So Yeon Jeon, Eun Kyung Choi
    Journal of Korean Medical Science.2024;[Epub]     CrossRef
  • Comparison of factors influencing the decision to withdraw life-sustaining treatment in intensive care unit patients after implementation of the Life-Sustaining Treatment Act in Korea
    Claire Junga Kim, Kyung Sook Hong, Sooyoung Cho, Jin Park
    Acute and Critical Care.2024; 39(2): 294.     CrossRef
  • Issues and implications of the life-sustaining treatment decision act: comparing the data from the survey and clinical data of inpatients at the end-of-life process
    Eunjeong Song, Dongsoon Shin, Jooseon Lee, Seonyoung Yun, Minjeong Eom, Suhee Oh, Heejung Lee, Jiwan Lee, Rhayun Song
    BMC Medical Ethics.2024;[Epub]     CrossRef
  • Development and Feasibility Evaluation of Smart Cancer Care 2.0 Based on Patient-Reported Outcomes for Post-Discharge Management of Patients with Cancer
    Jin Ah Kwon, Songsoo Yang, Su-Jin Koh, Young Ju Noh, Dong Yoon Kang, Sol Bin Yang, Eun Ji Kwon, Jeong-Wook Seo, Jin sung Kim, Minsu Ock
    Cancer Research and Treatment.2024; 56(4): 1040.     CrossRef
  • Advance Care Planning in South Korea
    Yu Jung Kim, Sun-Hyun Kim
    Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen.2023; 180: 68.     CrossRef
  • Preferred versus Actual Place of Care and Factors Associated with Home Discharge among Korean Patients with Advanced Cancer: A Retrospective Cohort Study
    In Young Hwang, Yohan Han, Min Sun Kim, Kyae Hyung Kim, Belong Cho, Wonho Choi, Yejin Kim, Shin Hye Yoo, Sun Young Lee
    Healthcare.2023; 11(13): 1939.     CrossRef
  • 9,208 View
  • 211 Download
  • 13 Web of Science
  • 13 Crossref
Close layer
Lung Cancer
Clinical Significance of Acute Kidney Injury in Lung Cancer Patients
Semin Cho, Eunjeong Kang, Ji Eun Kim, U Kang, Hee Gyung Kang, Minsu Park, Kwangsoo Kim, Dong Ki Kim, Kwon Wook Joo, Yon Su Kim, Hyung-Jin Yoon, Hajeong Lee
Cancer Res Treat. 2021;53(4):1015-1023.   Published online January 18, 2021
DOI: https://doi.org/10.4143/crt.2020.1010
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Acute kidney injury (AKI) in cancer patients is associated with increased morbidity and mortality. The incidence of AKI in lung cancer seems to be relatively higher compared with other solid organ malignancies, although its impact on patient outcomes remains unclear.
Materials and Methods
The patients newly diagnosed with lung cancer from 2004 to 2013 were enrolled in this retrospective cohort study. The patients were categorized according to the presence and severity of AKI. We compared all-cause mortality and long-term renal outcome according to AKI stage.
Results
A total of 3,202 patients were included in the final analysis. AKI occurred in 1,783 (55.7%) patients during the follow-up period, with the majority having mild AKI stage 1 (75.8%). During the follow-up of 2.6±2.2 years, total 1,251 patients (53.7%) were died and 5-year survival rate was 46.9%. We found that both AKI development and severity were independent risk factors for all-cause mortality in lung cancer patients, even after adjustment for lung cancer-specific variables including the stage or pathological type. In addition, patients suffered from more severe AKI tend to encounter de novo chronic kidney disease development, worsening kidney function, and end-stage kidney disease progression.
Conclusion
In this study, more than half of the lung cancer patients experienced AKI during their diagnosis and treatment period. Moreover, AKI occurrence and more advanced AKI were associated with a higher mortality risk and adverse kidney outcomes.

Citations

Citations to this article as recorded by  
  • Long-term risks of adverse kidney outcomes after acute kidney injury: a systematic review and meta-analysis
    Denise M J Veltkamp, Cindy P Porras, Christina M Gant, Wouter M Tiel Groenestege, Maarten B Kok, Marianne C Verhaar, Wouter W van Solinge, Saskia Haitjema, Robin W M Vernooij
    Nephrology Dialysis Transplantation.2025; 40(11): 2143.     CrossRef
  • Acute kidney injury: pathogenesis and therapeutic interventions
    Xiaoqin Xu, Tingting Zeng, Si Chen, Na Tian, Chunying Zhang, Yuemei Chen, Shanying Deng, Zhigang Mao, Juan Liao, Tonghao Zhang, Yi He, Wei Wang, Pan Chen, Yali Song
    Molecular Biomedicine.2025;[Epub]     CrossRef
  • External validation and comparison of clinical prediction models for cisplatin-associated acute kidney injury: a single-centre retrospective study
    Kazuki Saito, Satoru Nihei, Junichi Asaka, Kenzo Kudo
    Journal of Pharmaceutical Health Care and Sciences.2025;[Epub]     CrossRef
  • Updating Predictive Model for Cisplatin‐Induced Acute Kidney Injury: Incorporating Concomitant Medications and the Standard Supportive Care
    Kazuki Saito, Satoru Nihei, Junichi Asaka, Kenzo Kudo, Srijoni Sengupta
    International Journal of Nephrology.2025;[Epub]     CrossRef
  • Acute kidney injury associated with anti-PD-1 and anti-PD-L1 drugs: a meta-analysis of randomized clinical trials
    Isabela Gonçalves Lima, Isabele Benck Usiro Cabral da Silva, Vitória Carpentieri Pípolo, Vinicius Daher Alvares Delfino, Paulo Roberto Bignardi
    Immunopharmacology and Immunotoxicology.2024; 46(4): 470.     CrossRef
  • Prevalence of kidney disease in patients with different types of cancer or hematological malignancies: a cross-sectional study
    Feng Wu, Shiyuan Wang, Jialing Zhang, Peixin Wang, Aihua Zhang
    International Urology and Nephrology.2024; 56(12): 3835.     CrossRef
  • Protective effect of reduced glutathione on acute kidney injury in lung cancer patients treated with cisplatin: a retrospective cohort study
    Ying Huang, Yang Li, Xialian Xu, Jie Teng, Xiaoqiang Ding, Jiarui Xu
    Renal Failure.2024;[Epub]     CrossRef
  • Association between renal dysfunction and outcomes of lung cancer: A systematic review and meta‑analysis
    Huijuan Qian, Si Li, Ziyun Hu
    Oncology Letters.2024;[Epub]     CrossRef
  • Leveraging Explainable Machine Learning to Uncover the Association between Risk Factors and Major Cancers: Cancer Risk Factor Association Study (Preprint)
    Xiayuan Huang, ShuShun Ren, Xinyue Mao, Serena Chen, Elle Chen, Yuqi He, Yun Jiang
    JMIR Cancer.2024;[Epub]     CrossRef
  • Association and prediction of red blood cell distribution width to albumin ratio in all-cause mortality of acute kidney injury in critically ill patients
    Chen Gao, Longkai Peng
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • Point of care ultrasonography in onco-nephrology: A stride toward better physical examination
    Bhavna Bhasin-Chhabra, Abhilash Koratala
    World Journal of Nephrology.2023; 12(2): 29.     CrossRef
  • Protocolo diagnóstico y tratamiento de la nefropatía en los pacientes con neoplasia sólida
    Rodríguez Doyágüez, M.P. Morán Magro, C.M. Durán López, P. Martínez Miguel
    Medicine - Programa de Formación Médica Continuada Acreditado.2023; 13(82): 4870.     CrossRef
  • 9,419 View
  • 203 Download
  • 11 Web of Science
  • 12 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP